JP5927518B2 - N1−環状アミン−n5−置換フェニルビグアニド誘導体、それの調製方法及びそれを含む医薬組成物 - Google Patents
N1−環状アミン−n5−置換フェニルビグアニド誘導体、それの調製方法及びそれを含む医薬組成物 Download PDFInfo
- Publication number
- JP5927518B2 JP5927518B2 JP2014524932A JP2014524932A JP5927518B2 JP 5927518 B2 JP5927518 B2 JP 5927518B2 JP 2014524932 A JP2014524932 A JP 2014524932A JP 2014524932 A JP2014524932 A JP 2014524932A JP 5927518 B2 JP5927518 B2 JP 5927518B2
- Authority
- JP
- Japan
- Prior art keywords
- carbamimidoyl
- carboximidamide
- acid
- phenyl
- piperidine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000008194 pharmaceutical composition Substances 0.000 title claims description 18
- 238000000034 method Methods 0.000 title description 17
- 238000002360 preparation method Methods 0.000 title description 12
- 150000004288 phenylbiguanides Chemical class 0.000 title description 4
- 150000001875 compounds Chemical class 0.000 claims description 91
- 206010028980 Neoplasm Diseases 0.000 claims description 48
- 201000011510 cancer Diseases 0.000 claims description 47
- 125000000217 alkyl group Chemical group 0.000 claims description 40
- 150000003839 salts Chemical class 0.000 claims description 38
- -1 N- (3,4-difluorophenyl) carbamimidoyl Chemical group 0.000 claims description 31
- 125000003545 alkoxy group Chemical group 0.000 claims description 24
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 22
- 229910052736 halogen Inorganic materials 0.000 claims description 18
- 239000003814 drug Substances 0.000 claims description 17
- 150000002367 halogens Chemical class 0.000 claims description 17
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 17
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 15
- 125000004435 hydrogen atom Chemical class [H]* 0.000 claims description 15
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 15
- 239000002253 acid Substances 0.000 claims description 14
- 229910052757 nitrogen Inorganic materials 0.000 claims description 14
- 125000001424 substituent group Chemical group 0.000 claims description 14
- 238000011282 treatment Methods 0.000 claims description 14
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims description 12
- 239000004480 active ingredient Substances 0.000 claims description 12
- 201000010099 disease Diseases 0.000 claims description 12
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims description 11
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 claims description 10
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 10
- 206010006187 Breast cancer Diseases 0.000 claims description 9
- 208000026310 Breast neoplasm Diseases 0.000 claims description 9
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 claims description 9
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 claims description 9
- 206010012601 diabetes mellitus Diseases 0.000 claims description 9
- 239000000203 mixture Substances 0.000 claims description 9
- 239000003960 organic solvent Substances 0.000 claims description 8
- 125000000719 pyrrolidinyl group Chemical group 0.000 claims description 8
- 206010027476 Metastases Diseases 0.000 claims description 7
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims description 7
- 230000009401 metastasis Effects 0.000 claims description 7
- 125000003386 piperidinyl group Chemical group 0.000 claims description 7
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims description 6
- LSNNMFCWUKXFEE-UHFFFAOYSA-M Bisulfite Chemical compound OS([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-M 0.000 claims description 6
- FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Chemical compound CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 claims description 6
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 claims description 6
- AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Chemical compound OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 claims description 6
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 claims description 6
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 claims description 6
- 125000004397 aminosulfonyl group Chemical group NS(=O)(=O)* 0.000 claims description 6
- RWZYAGGXGHYGMB-UHFFFAOYSA-N anthranilic acid Chemical compound NC1=CC=CC=C1C(O)=O RWZYAGGXGHYGMB-UHFFFAOYSA-N 0.000 claims description 6
- 125000003725 azepanyl group Chemical group 0.000 claims description 6
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 claims description 6
- JXTHNDFMNIQAHM-UHFFFAOYSA-N dichloroacetic acid Chemical compound OC(=O)C(Cl)Cl JXTHNDFMNIQAHM-UHFFFAOYSA-N 0.000 claims description 6
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 claims description 6
- KQNPFQTWMSNSAP-UHFFFAOYSA-N isobutyric acid Chemical compound CC(C)C(O)=O KQNPFQTWMSNSAP-UHFFFAOYSA-N 0.000 claims description 6
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 claims description 6
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 claims description 6
- XNGIFLGASWRNHJ-UHFFFAOYSA-N phthalic acid Chemical compound OC(=O)C1=CC=CC=C1C(O)=O XNGIFLGASWRNHJ-UHFFFAOYSA-N 0.000 claims description 6
- 125000004193 piperazinyl group Chemical group 0.000 claims description 6
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 6
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 claims description 6
- 125000003831 tetrazolyl group Chemical group 0.000 claims description 6
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 claims description 6
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 claims description 6
- 125000006700 (C1-C6) alkylthio group Chemical group 0.000 claims description 5
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 claims description 5
- 208000004930 Fatty Liver Diseases 0.000 claims description 5
- 206010019708 Hepatic steatosis Diseases 0.000 claims description 5
- 208000035150 Hypercholesterolemia Diseases 0.000 claims description 5
- 208000031226 Hyperlipidaemia Diseases 0.000 claims description 5
- 208000001145 Metabolic Syndrome Diseases 0.000 claims description 5
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 claims description 5
- 208000008589 Obesity Diseases 0.000 claims description 5
- 208000001132 Osteoporosis Diseases 0.000 claims description 5
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 claims description 5
- 125000004422 alkyl sulphonamide group Chemical group 0.000 claims description 5
- 125000002393 azetidinyl group Chemical group 0.000 claims description 5
- 208000010706 fatty liver disease Diseases 0.000 claims description 5
- BEBCJVAWIBVWNZ-UHFFFAOYSA-N glycinamide Chemical compound NCC(N)=O BEBCJVAWIBVWNZ-UHFFFAOYSA-N 0.000 claims description 5
- 229910052739 hydrogen Inorganic materials 0.000 claims description 5
- 239000001257 hydrogen Substances 0.000 claims description 5
- 229910017604 nitric acid Inorganic materials 0.000 claims description 5
- 235000020824 obesity Nutrition 0.000 claims description 5
- 201000010065 polycystic ovary syndrome Diseases 0.000 claims description 5
- 231100000240 steatosis hepatitis Toxicity 0.000 claims description 5
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 claims description 4
- 235000011054 acetic acid Nutrition 0.000 claims description 4
- 208000029078 coronary artery disease Diseases 0.000 claims description 4
- 239000008187 granular material Substances 0.000 claims description 4
- 125000004438 haloalkoxy group Chemical group 0.000 claims description 4
- 125000001188 haloalkyl group Chemical group 0.000 claims description 4
- QUUYRYYUKNNNNS-UHFFFAOYSA-N piperidine-1-carboximidamide Chemical compound NC(=N)N1CCCCC1 QUUYRYYUKNNNNS-UHFFFAOYSA-N 0.000 claims description 4
- 239000003826 tablet Substances 0.000 claims description 4
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 claims description 3
- NQRKYASMKDDGHT-UHFFFAOYSA-N (aminooxy)acetic acid Chemical compound NOCC(O)=O NQRKYASMKDDGHT-UHFFFAOYSA-N 0.000 claims description 3
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 claims description 3
- 239000005711 Benzoic acid Substances 0.000 claims description 3
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 claims description 3
- IAJILQKETJEXLJ-UHFFFAOYSA-N Galacturonsaeure Natural products O=CC(O)C(O)C(O)C(O)C(O)=O IAJILQKETJEXLJ-UHFFFAOYSA-N 0.000 claims description 3
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 claims description 3
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 claims description 3
- SOWBFZRMHSNYGE-UHFFFAOYSA-N Monoamide-Oxalic acid Natural products NC(=O)C(O)=O SOWBFZRMHSNYGE-UHFFFAOYSA-N 0.000 claims description 3
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 claims description 3
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 claims description 3
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 claims description 3
- IAJILQKETJEXLJ-QTBDOELSSA-N aldehydo-D-glucuronic acid Chemical compound O=C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)C(O)=O IAJILQKETJEXLJ-QTBDOELSSA-N 0.000 claims description 3
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 claims description 3
- 229910000147 aluminium phosphate Inorganic materials 0.000 claims description 3
- 235000010323 ascorbic acid Nutrition 0.000 claims description 3
- 239000011668 ascorbic acid Substances 0.000 claims description 3
- 229960005070 ascorbic acid Drugs 0.000 claims description 3
- SRSXLGNVWSONIS-UHFFFAOYSA-N benzenesulfonic acid Chemical compound OS(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-N 0.000 claims description 3
- 229940092714 benzenesulfonic acid Drugs 0.000 claims description 3
- 235000010233 benzoic acid Nutrition 0.000 claims description 3
- KGBXLFKZBHKPEV-UHFFFAOYSA-N boric acid Chemical compound OB(O)O KGBXLFKZBHKPEV-UHFFFAOYSA-N 0.000 claims description 3
- 239000004327 boric acid Substances 0.000 claims description 3
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 claims description 3
- BVKZGUZCCUSVTD-UHFFFAOYSA-N carbonic acid Chemical compound OC(O)=O BVKZGUZCCUSVTD-UHFFFAOYSA-N 0.000 claims description 3
- QWJNFFYFEKXZBF-UHFFFAOYSA-N cyanocyanamide Chemical compound N#CNC#N QWJNFFYFEKXZBF-UHFFFAOYSA-N 0.000 claims description 3
- 229960005215 dichloroacetic acid Drugs 0.000 claims description 3
- 235000019253 formic acid Nutrition 0.000 claims description 3
- 239000001530 fumaric acid Substances 0.000 claims description 3
- 229940097043 glucuronic acid Drugs 0.000 claims description 3
- 239000004220 glutamic acid Substances 0.000 claims description 3
- 235000013922 glutamic acid Nutrition 0.000 claims description 3
- 239000004310 lactic acid Substances 0.000 claims description 3
- 235000014655 lactic acid Nutrition 0.000 claims description 3
- 239000007788 liquid Substances 0.000 claims description 3
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 claims description 3
- 239000011976 maleic acid Substances 0.000 claims description 3
- 239000001630 malic acid Substances 0.000 claims description 3
- 235000011090 malic acid Nutrition 0.000 claims description 3
- 238000004519 manufacturing process Methods 0.000 claims description 3
- QEBLCOXEDJODND-UHFFFAOYSA-N n'-[n'-[4-(trifluoromethyl)phenyl]carbamimidoyl]pyrrolidine-1-carboximidamide Chemical compound C=1C=C(C(F)(F)F)C=CC=1N=C(N)\N=C(/N)N1CCCC1 QEBLCOXEDJODND-UHFFFAOYSA-N 0.000 claims description 3
- 235000006408 oxalic acid Nutrition 0.000 claims description 3
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 claims description 3
- 235000019260 propionic acid Nutrition 0.000 claims description 3
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 claims description 3
- 229960004889 salicylic acid Drugs 0.000 claims description 3
- JDVPQXZIJDEHAN-UHFFFAOYSA-N succinamic acid Chemical compound NC(=O)CCC(O)=O JDVPQXZIJDEHAN-UHFFFAOYSA-N 0.000 claims description 3
- 235000002906 tartaric acid Nutrition 0.000 claims description 3
- 239000011975 tartaric acid Substances 0.000 claims description 3
- YHHGCCCYCQSSFN-UHFFFAOYSA-N 4-[[amino-[[amino(piperidin-1-yl)methylidene]amino]methylidene]amino]benzenesulfonic acid Chemical compound C=1C=C(S(O)(=O)=O)C=CC=1N=C(N)\N=C(\N)N1CCCCC1 YHHGCCCYCQSSFN-UHFFFAOYSA-N 0.000 claims description 2
- 206010009944 Colon cancer Diseases 0.000 claims description 2
- 208000000112 Myalgia Diseases 0.000 claims description 2
- 206010039020 Rhabdomyolysis Diseases 0.000 claims description 2
- 239000002775 capsule Substances 0.000 claims description 2
- 230000005779 cell damage Effects 0.000 claims description 2
- 208000037887 cell injury Diseases 0.000 claims description 2
- 235000015165 citric acid Nutrition 0.000 claims description 2
- 208000029742 colonic neoplasm Diseases 0.000 claims description 2
- 239000007924 injection Substances 0.000 claims description 2
- 238000002347 injection Methods 0.000 claims description 2
- 229940098779 methanesulfonic acid Drugs 0.000 claims description 2
- 210000000663 muscle cell Anatomy 0.000 claims description 2
- 208000013465 muscle pain Diseases 0.000 claims description 2
- PFVVABPYUGLPMC-UHFFFAOYSA-N n'-[n'-(3,4,5-trifluorophenyl)carbamimidoyl]piperidine-1-carboximidamide Chemical compound C=1C(F)=C(F)C(F)=CC=1N=C(N)\N=C(/N)N1CCCCC1 PFVVABPYUGLPMC-UHFFFAOYSA-N 0.000 claims description 2
- BQRPNQFFOAQVCZ-UHFFFAOYSA-N n'-[n'-(3,4-dichlorophenyl)carbamimidoyl]piperidine-1-carboximidamide Chemical compound C=1C=C(Cl)C(Cl)=CC=1N=C(N)\N=C(/N)N1CCCCC1 BQRPNQFFOAQVCZ-UHFFFAOYSA-N 0.000 claims description 2
- AWBOIWDSMZHASX-UHFFFAOYSA-N n'-[n'-(3,4-dichlorophenyl)carbamimidoyl]pyrrolidine-1-carboximidamide Chemical compound C=1C=C(Cl)C(Cl)=CC=1N=C(N)\N=C(/N)N1CCCC1 AWBOIWDSMZHASX-UHFFFAOYSA-N 0.000 claims description 2
- AJJLYOLFOIAJQI-UHFFFAOYSA-N n'-[n'-(3,5-dichlorophenyl)carbamimidoyl]piperidine-1-carboximidamide Chemical compound C=1C(Cl)=CC(Cl)=CC=1N=C(N)\N=C(/N)N1CCCCC1 AJJLYOLFOIAJQI-UHFFFAOYSA-N 0.000 claims description 2
- XHBSAUSRSUTLIR-UHFFFAOYSA-N n'-[n'-(3-aminophenyl)carbamimidoyl]piperidine-1-carboximidamide Chemical compound C=1C=CC(N)=CC=1N=C(N)\N=C(/N)N1CCCCC1 XHBSAUSRSUTLIR-UHFFFAOYSA-N 0.000 claims description 2
- QSVDXHMVNYXJLM-UHFFFAOYSA-N n'-[n'-(3-bromophenyl)carbamimidoyl]piperidine-1-carboximidamide Chemical compound C=1C=CC(Br)=CC=1N=C(N)\N=C(/N)N1CCCCC1 QSVDXHMVNYXJLM-UHFFFAOYSA-N 0.000 claims description 2
- BYLKVZZHBBNRRC-UHFFFAOYSA-N n'-[n'-(3-chlorophenyl)carbamimidoyl]azepane-1-carboximidamide Chemical compound C=1C=CC(Cl)=CC=1N=C(N)\N=C(/N)N1CCCCCC1 BYLKVZZHBBNRRC-UHFFFAOYSA-N 0.000 claims description 2
- ZLNKIOGFXSDVHP-UHFFFAOYSA-N n'-[n'-(3-chlorophenyl)carbamimidoyl]piperidine-1-carboximidamide Chemical compound C=1C=CC(Cl)=CC=1N=C(N)\N=C(/N)N1CCCCC1 ZLNKIOGFXSDVHP-UHFFFAOYSA-N 0.000 claims description 2
- XWNPKFCFRCXFDF-UHFFFAOYSA-N n'-[n'-(3-chlorophenyl)carbamimidoyl]pyrrolidine-1-carboximidamide Chemical compound C=1C=CC(Cl)=CC=1N=C(N)\N=C(/N)N1CCCC1 XWNPKFCFRCXFDF-UHFFFAOYSA-N 0.000 claims description 2
- GHGFBISUUIYCOJ-UHFFFAOYSA-N n'-[n'-(3-ethylphenyl)carbamimidoyl]piperidine-1-carboximidamide Chemical compound CCC1=CC=CC(N=C(N)\N=C(/N)N2CCCCC2)=C1 GHGFBISUUIYCOJ-UHFFFAOYSA-N 0.000 claims description 2
- PTITWBIQIVPDHV-UHFFFAOYSA-N n'-[n'-(3-fluorophenyl)carbamimidoyl]piperidine-1-carboximidamide Chemical compound C=1C=CC(F)=CC=1N=C(N)\N=C(/N)N1CCCCC1 PTITWBIQIVPDHV-UHFFFAOYSA-N 0.000 claims description 2
- LJUVXUZCILBHCS-UHFFFAOYSA-N n'-[n'-(3-hydroxyphenyl)carbamimidoyl]piperidine-1-carboximidamide Chemical compound C=1C=CC(O)=CC=1N=C(N)\N=C(/N)N1CCCCC1 LJUVXUZCILBHCS-UHFFFAOYSA-N 0.000 claims description 2
- YUXFYCBQXKAGMG-UHFFFAOYSA-N n'-[n'-(4-methylsulfanylphenyl)carbamimidoyl]piperidine-1-carboximidamide Chemical compound C1=CC(SC)=CC=C1N=C(N)\N=C(/N)N1CCCCC1 YUXFYCBQXKAGMG-UHFFFAOYSA-N 0.000 claims description 2
- DIYPDTQNOOTLOY-UHFFFAOYSA-N n'-[n'-(4-sulfamoylphenyl)carbamimidoyl]piperidine-1-carboximidamide Chemical compound C=1C=C(S(N)(=O)=O)C=CC=1N=C(N)\N=C(\N)N1CCCCC1 DIYPDTQNOOTLOY-UHFFFAOYSA-N 0.000 claims description 2
- SGDDDNWOSNYFPR-UHFFFAOYSA-N n'-[n'-[3-(difluoromethoxy)phenyl]carbamimidoyl]piperidine-1-carboximidamide Chemical compound C=1C=CC(OC(F)F)=CC=1N=C(N)\N=C(/N)N1CCCCC1 SGDDDNWOSNYFPR-UHFFFAOYSA-N 0.000 claims description 2
- NXOBVEQJPINHOK-UHFFFAOYSA-N n'-[n'-[3-(hydroxymethyl)phenyl]carbamimidoyl]piperidine-1-carboximidamide Chemical compound C=1C=CC(CO)=CC=1N=C(N)\N=C(/N)N1CCCCC1 NXOBVEQJPINHOK-UHFFFAOYSA-N 0.000 claims description 2
- CKKFKWCGIOFALO-UHFFFAOYSA-N n'-[n'-[3-(methanesulfonamido)phenyl]carbamimidoyl]piperidine-1-carboximidamide Chemical compound CS(=O)(=O)NC1=CC=CC(N=C(N)\N=C(/N)N2CCCCC2)=C1 CKKFKWCGIOFALO-UHFFFAOYSA-N 0.000 claims description 2
- ITJVBIYXLUTENM-UHFFFAOYSA-N n'-[n'-[3-(trifluoromethoxy)phenyl]carbamimidoyl]piperidine-1-carboximidamide Chemical compound C=1C=CC(OC(F)(F)F)=CC=1N=C(N)\N=C(\N)N1CCCCC1 ITJVBIYXLUTENM-UHFFFAOYSA-N 0.000 claims description 2
- ZZYILPKNAJUMLU-UHFFFAOYSA-N n'-[n'-[3-(trifluoromethoxy)phenyl]carbamimidoyl]pyrrolidine-1-carboximidamide Chemical compound C=1C=CC(OC(F)(F)F)=CC=1N=C(N)\N=C(/N)N1CCCC1 ZZYILPKNAJUMLU-UHFFFAOYSA-N 0.000 claims description 2
- FVEVBICEWGSERK-UHFFFAOYSA-N n'-[n'-[3-(trifluoromethyl)phenyl]carbamimidoyl]piperidine-1-carboximidamide Chemical compound C=1C=CC(C(F)(F)F)=CC=1N=C(N)\N=C(/N)N1CCCCC1 FVEVBICEWGSERK-UHFFFAOYSA-N 0.000 claims description 2
- DNTINNVIIFDNPO-UHFFFAOYSA-N n'-[n'-[3-(trifluoromethyl)phenyl]carbamimidoyl]pyrrolidine-1-carboximidamide Chemical compound C=1C=CC(C(F)(F)F)=CC=1N=C(N)\N=C(\N)N1CCCC1 DNTINNVIIFDNPO-UHFFFAOYSA-N 0.000 claims description 2
- DLTYVSKLXPIBRO-UHFFFAOYSA-N n'-[n'-[3-bromo-5-(trifluoromethoxy)phenyl]carbamimidoyl]piperidine-1-carboximidamide Chemical compound C=1C(Br)=CC(OC(F)(F)F)=CC=1N=C(N)\N=C(\N)N1CCCCC1 DLTYVSKLXPIBRO-UHFFFAOYSA-N 0.000 claims description 2
- DQJFTAOTWWCUMA-UHFFFAOYSA-N n'-[n'-[3-bromo-5-(trifluoromethoxy)phenyl]carbamimidoyl]pyrrolidine-1-carboximidamide Chemical compound C=1C(Br)=CC(OC(F)(F)F)=CC=1N=C(N)\N=C(/N)N1CCCC1 DQJFTAOTWWCUMA-UHFFFAOYSA-N 0.000 claims description 2
- DXCXNBVIDBORTD-UHFFFAOYSA-N n'-[n'-[3-chloro-4-(trifluoromethoxy)phenyl]carbamimidoyl]azetidine-1-carboximidamide Chemical compound C=1C=C(OC(F)(F)F)C(Cl)=CC=1N=C(N)\N=C(/N)N1CCC1 DXCXNBVIDBORTD-UHFFFAOYSA-N 0.000 claims description 2
- JGCHWEAKUMWYKD-UHFFFAOYSA-N n'-[n'-[3-chloro-4-(trifluoromethoxy)phenyl]carbamimidoyl]piperidine-1-carboximidamide Chemical compound C=1C=C(OC(F)(F)F)C(Cl)=CC=1N=C(N)\N=C(\N)N1CCCCC1 JGCHWEAKUMWYKD-UHFFFAOYSA-N 0.000 claims description 2
- QHQDFFHWXRZVKZ-UHFFFAOYSA-N n'-[n'-[3-chloro-4-(trifluoromethoxy)phenyl]carbamimidoyl]pyrrolidine-1-carboximidamide Chemical compound C=1C=C(OC(F)(F)F)C(Cl)=CC=1N=C(N)\N=C(/N)N1CCCC1 QHQDFFHWXRZVKZ-UHFFFAOYSA-N 0.000 claims description 2
- SQEVLDQPPXIORY-UHFFFAOYSA-N n'-[n'-[3-chloro-5-(trifluoromethoxy)phenyl]carbamimidoyl]piperidine-1-carboximidamide Chemical compound C=1C(Cl)=CC(OC(F)(F)F)=CC=1N=C(N)\N=C(\N)N1CCCCC1 SQEVLDQPPXIORY-UHFFFAOYSA-N 0.000 claims description 2
- SLKFKZWERTXLLH-UHFFFAOYSA-N n'-[n'-[3-fluoro-4-(trifluoromethoxy)phenyl]carbamimidoyl]azetidine-1-carboximidamide Chemical compound C=1C=C(OC(F)(F)F)C(F)=CC=1N=C(N)\N=C(/N)N1CCC1 SLKFKZWERTXLLH-UHFFFAOYSA-N 0.000 claims description 2
- GRQMQGWVQCAOGF-UHFFFAOYSA-N n'-[n'-[3-fluoro-4-(trifluoromethoxy)phenyl]carbamimidoyl]piperidine-1-carboximidamide Chemical compound C=1C=C(OC(F)(F)F)C(F)=CC=1N=C(N)\N=C(/N)N1CCCCC1 GRQMQGWVQCAOGF-UHFFFAOYSA-N 0.000 claims description 2
- YVGKURXTZMKIKK-UHFFFAOYSA-N n'-[n'-[3-fluoro-4-(trifluoromethoxy)phenyl]carbamimidoyl]pyrrolidine-1-carboximidamide Chemical compound C=1C=C(OC(F)(F)F)C(F)=CC=1N=C(N)\N=C(\N)N1CCCC1 YVGKURXTZMKIKK-UHFFFAOYSA-N 0.000 claims description 2
- AQGADWOAGPWTDE-UHFFFAOYSA-N n'-[n'-[3-fluoro-4-(trifluoromethyl)phenyl]carbamimidoyl]piperidine-1-carboximidamide Chemical compound C=1C=C(C(F)(F)F)C(F)=CC=1N=C(N)\N=C(/N)N1CCCCC1 AQGADWOAGPWTDE-UHFFFAOYSA-N 0.000 claims description 2
- NFECPXURKUTTGH-UHFFFAOYSA-N n'-[n'-[3-fluoro-4-(trifluoromethyl)phenyl]carbamimidoyl]pyrrolidine-1-carboximidamide Chemical compound C=1C=C(C(F)(F)F)C(F)=CC=1N=C(N)\N=C(\N)N1CCCC1 NFECPXURKUTTGH-UHFFFAOYSA-N 0.000 claims description 2
- WRMVJSUCTHKNGH-UHFFFAOYSA-N n'-[n'-[4-(2h-tetrazol-5-yl)phenyl]carbamimidoyl]piperidine-1-carboximidamide Chemical compound C=1C=C(C2=NNN=N2)C=CC=1N=C(N)\N=C(/N)N1CCCCC1 WRMVJSUCTHKNGH-UHFFFAOYSA-N 0.000 claims description 2
- MLUAQOHQPZDOHM-UHFFFAOYSA-N n'-[n'-[4-(dimethylamino)phenyl]carbamimidoyl]piperidine-1-carboximidamide Chemical compound C1=CC(N(C)C)=CC=C1N=C(N)\N=C(/N)N1CCCCC1 MLUAQOHQPZDOHM-UHFFFAOYSA-N 0.000 claims description 2
- WCWZHEGOOZVDPC-UHFFFAOYSA-N n'-[n'-[4-(trifluoromethoxy)phenyl]carbamimidoyl]azetidine-1-carboximidamide Chemical compound C=1C=C(OC(F)(F)F)C=CC=1N=C(N)\N=C(\N)N1CCC1 WCWZHEGOOZVDPC-UHFFFAOYSA-N 0.000 claims description 2
- WGMMCGKZKMHNCO-UHFFFAOYSA-N n'-[n'-[4-(trifluoromethoxy)phenyl]carbamimidoyl]piperidine-1-carboximidamide Chemical compound C=1C=C(OC(F)(F)F)C=CC=1N=C(N)\N=C(\N)N1CCCCC1 WGMMCGKZKMHNCO-UHFFFAOYSA-N 0.000 claims description 2
- NGFUHJWVBKTNOE-UHFFFAOYSA-N n'-[n'-[4-(trifluoromethoxy)phenyl]carbamimidoyl]pyrrolidine-1-carboximidamide Chemical compound C=1C=C(OC(F)(F)F)C=CC=1N=C(N)\N=C(/N)N1CCCC1 NGFUHJWVBKTNOE-UHFFFAOYSA-N 0.000 claims description 2
- WUVWZMQCXHZKMK-UHFFFAOYSA-N n'-[n'-[4-(trifluoromethyl)phenyl]carbamimidoyl]azetidine-1-carboximidamide Chemical compound C=1C=C(C(F)(F)F)C=CC=1N=C(N)\N=C(/N)N1CCC1 WUVWZMQCXHZKMK-UHFFFAOYSA-N 0.000 claims description 2
- JUENJXIBKXNZCQ-UHFFFAOYSA-N n'-[n'-[4-(trifluoromethyl)phenyl]carbamimidoyl]piperidine-1-carboximidamide Chemical compound C=1C=C(C(F)(F)F)C=CC=1N=C(N)\N=C(\N)N1CCCCC1 JUENJXIBKXNZCQ-UHFFFAOYSA-N 0.000 claims description 2
- JJMHJVDBCPFXEF-UHFFFAOYSA-N n'-[n'-[4-chloro-3-(trifluoromethoxy)phenyl]carbamimidoyl]piperidine-1-carboximidamide Chemical compound C=1C=C(Cl)C(OC(F)(F)F)=CC=1N=C(N)\N=C(/N)N1CCCCC1 JJMHJVDBCPFXEF-UHFFFAOYSA-N 0.000 claims description 2
- NNTUKYPSVYIXII-UHFFFAOYSA-N n'-[n'-[4-chloro-3-(trifluoromethyl)phenyl]carbamimidoyl]piperidine-1-carboximidamide Chemical compound C=1C=C(Cl)C(C(F)(F)F)=CC=1N=C(N)\N=C(/N)N1CCCCC1 NNTUKYPSVYIXII-UHFFFAOYSA-N 0.000 claims description 2
- IEOWYBZWZWIPMN-UHFFFAOYSA-N n'-[n'-[4-fluoro-3-(trifluoromethoxy)phenyl]carbamimidoyl]piperidine-1-carboximidamide Chemical compound C=1C=C(F)C(OC(F)(F)F)=CC=1N=C(N)\N=C(\N)N1CCCCC1 IEOWYBZWZWIPMN-UHFFFAOYSA-N 0.000 claims description 2
- SOARXXJOEYYCCX-UHFFFAOYSA-N n'-[n'-[4-fluoro-3-(trifluoromethyl)phenyl]carbamimidoyl]piperidine-1-carboximidamide Chemical compound C=1C=C(F)C(C(F)(F)F)=CC=1N=C(N)\N=C(\N)N1CCCCC1 SOARXXJOEYYCCX-UHFFFAOYSA-N 0.000 claims description 2
- CYJLOTZCBRJOPX-UHFFFAOYSA-N n-[3-[[amino-[[amino(piperidin-1-yl)methylidene]amino]methylidene]amino]phenyl]acetamide Chemical compound CC(=O)NC1=CC=CC(N=C(N)\N=C(/N)N2CCCCC2)=C1 CYJLOTZCBRJOPX-UHFFFAOYSA-N 0.000 claims description 2
- PIKIXZCLHOHMBD-UHFFFAOYSA-N n-[4-[[amino-[[amino(piperidin-1-yl)methylidene]amino]methylidene]amino]phenyl]acetamide Chemical compound C1=CC(NC(=O)C)=CC=C1N=C(N)\N=C(/N)N1CCCCC1 PIKIXZCLHOHMBD-UHFFFAOYSA-N 0.000 claims description 2
- 239000006187 pill Substances 0.000 claims description 2
- 230000001629 suppression Effects 0.000 claims description 2
- 208000003174 Brain Neoplasms Diseases 0.000 claims 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 1
- 208000000453 Skin Neoplasms Diseases 0.000 claims 1
- 208000005718 Stomach Neoplasms Diseases 0.000 claims 1
- 208000002495 Uterine Neoplasms Diseases 0.000 claims 1
- 206010017758 gastric cancer Diseases 0.000 claims 1
- 201000005787 hematologic cancer Diseases 0.000 claims 1
- 208000024200 hematopoietic and lymphoid system neoplasm Diseases 0.000 claims 1
- 201000007270 liver cancer Diseases 0.000 claims 1
- 208000014018 liver neoplasm Diseases 0.000 claims 1
- 201000005202 lung cancer Diseases 0.000 claims 1
- 208000020816 lung neoplasm Diseases 0.000 claims 1
- ADAJEUUBAGEVMW-UHFFFAOYSA-N n'-[n'-(3,5-difluorophenyl)carbamimidoyl]piperidine-1-carboximidamide Chemical compound C=1C(F)=CC(F)=CC=1N=C(N)\N=C(/N)N1CCCCC1 ADAJEUUBAGEVMW-UHFFFAOYSA-N 0.000 claims 1
- 201000000849 skin cancer Diseases 0.000 claims 1
- 201000011549 stomach cancer Diseases 0.000 claims 1
- 206010046766 uterine cancer Diseases 0.000 claims 1
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 69
- 210000004027 cell Anatomy 0.000 description 52
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 24
- 102000014156 AMP-Activated Protein Kinases Human genes 0.000 description 20
- 108010011376 AMP-Activated Protein Kinases Proteins 0.000 description 20
- XZWYZXLIPXDOLR-UHFFFAOYSA-N metformin Chemical compound CN(C)C(=N)NC(N)=N XZWYZXLIPXDOLR-UHFFFAOYSA-N 0.000 description 20
- 239000000243 solution Substances 0.000 description 18
- 210000000130 stem cell Anatomy 0.000 description 15
- 150000004283 biguanides Chemical group 0.000 description 14
- 230000000694 effects Effects 0.000 description 14
- 239000007787 solid Substances 0.000 description 14
- 230000004913 activation Effects 0.000 description 13
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 12
- 229940079593 drug Drugs 0.000 description 12
- 229960003105 metformin Drugs 0.000 description 12
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 10
- 230000002401 inhibitory effect Effects 0.000 description 10
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 9
- 230000007705 epithelial mesenchymal transition Effects 0.000 description 9
- 230000010261 cell growth Effects 0.000 description 8
- QGBSISYHAICWAH-UHFFFAOYSA-N dicyandiamide Chemical compound NC(N)=NC#N QGBSISYHAICWAH-UHFFFAOYSA-N 0.000 description 8
- 125000005843 halogen group Chemical group 0.000 description 8
- OETHQSJEHLVLGH-UHFFFAOYSA-N metformin hydrochloride Chemical compound Cl.CN(C)C(=N)N=C(N)N OETHQSJEHLVLGH-UHFFFAOYSA-N 0.000 description 8
- 229960004329 metformin hydrochloride Drugs 0.000 description 8
- 241000237858 Gastropoda Species 0.000 description 7
- 238000006243 chemical reaction Methods 0.000 description 7
- 230000002829 reductive effect Effects 0.000 description 7
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 6
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 6
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 6
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 6
- 230000015572 biosynthetic process Effects 0.000 description 6
- 125000004432 carbon atom Chemical group C* 0.000 description 6
- 230000022131 cell cycle Effects 0.000 description 6
- 239000008103 glucose Substances 0.000 description 6
- 230000004563 mammosphere formation Effects 0.000 description 6
- 125000006413 ring segment Chemical group 0.000 description 6
- 238000003786 synthesis reaction Methods 0.000 description 6
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 5
- 239000000706 filtrate Substances 0.000 description 5
- 239000002609 medium Substances 0.000 description 5
- 239000011541 reaction mixture Substances 0.000 description 5
- 239000002904 solvent Substances 0.000 description 5
- 239000000758 substrate Substances 0.000 description 5
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 4
- AMQJEAYHLZJPGS-UHFFFAOYSA-N N-Pentanol Chemical compound CCCCCO AMQJEAYHLZJPGS-UHFFFAOYSA-N 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 125000004414 alkyl thio group Chemical group 0.000 description 4
- 239000002246 antineoplastic agent Substances 0.000 description 4
- 210000004369 blood Anatomy 0.000 description 4
- 239000008280 blood Substances 0.000 description 4
- 244000309466 calf Species 0.000 description 4
- 230000009702 cancer cell proliferation Effects 0.000 description 4
- 125000000753 cycloalkyl group Chemical group 0.000 description 4
- 238000005516 engineering process Methods 0.000 description 4
- 239000012458 free base Substances 0.000 description 4
- 125000000592 heterocycloalkyl group Chemical group 0.000 description 4
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 4
- 239000012528 membrane Substances 0.000 description 4
- YBYRMVIVWMBXKQ-UHFFFAOYSA-N phenylmethanesulfonyl fluoride Chemical compound FS(=O)(=O)CC1=CC=CC=C1 YBYRMVIVWMBXKQ-UHFFFAOYSA-N 0.000 description 4
- 238000010992 reflux Methods 0.000 description 4
- 210000002966 serum Anatomy 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- RWRDLPDLKQPQOW-UHFFFAOYSA-N tetrahydropyrrole Substances C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 description 4
- QMNAQPMXDMLOLD-UHFFFAOYSA-N 6-methyl-4-oxo-5,6-dihydrothieno[2,3-b]thiopyran-2-sulfonamide Chemical compound S1C(C)CC(=O)C2=C1SC(S(N)(=O)=O)=C2 QMNAQPMXDMLOLD-UHFFFAOYSA-N 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 108091023040 Transcription factor Proteins 0.000 description 3
- 102000040945 Transcription factor Human genes 0.000 description 3
- 125000003118 aryl group Chemical group 0.000 description 3
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 3
- 239000013592 cell lysate Substances 0.000 description 3
- 239000012141 concentrate Substances 0.000 description 3
- 239000012153 distilled water Substances 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 150000002430 hydrocarbons Chemical group 0.000 description 3
- 150000003840 hydrochlorides Chemical class 0.000 description 3
- 238000003018 immunoassay Methods 0.000 description 3
- 150000002632 lipids Chemical class 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 3
- 238000002156 mixing Methods 0.000 description 3
- 239000000546 pharmaceutical excipient Substances 0.000 description 3
- 230000000144 pharmacologic effect Effects 0.000 description 3
- 229960001753 phenformin hydrochloride Drugs 0.000 description 3
- 230000026731 phosphorylation Effects 0.000 description 3
- 238000006366 phosphorylation reaction Methods 0.000 description 3
- 235000018102 proteins Nutrition 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 239000011734 sodium Substances 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- NWUYHJFMYQTDRP-UHFFFAOYSA-N 1,2-bis(ethenyl)benzene;1-ethenyl-2-ethylbenzene;styrene Chemical compound C=CC1=CC=CC=C1.CCC1=CC=CC=C1C=C.C=CC1=CC=CC=C1C=C NWUYHJFMYQTDRP-UHFFFAOYSA-N 0.000 description 2
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 2
- AZKSAVLVSZKNRD-UHFFFAOYSA-M 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide Chemical compound [Br-].S1C(C)=C(C)N=C1[N+]1=NC(C=2C=CC=CC=2)=NN1C1=CC=CC=C1 AZKSAVLVSZKNRD-UHFFFAOYSA-M 0.000 description 2
- DHYHYLGCQVVLOQ-UHFFFAOYSA-N 3-bromoaniline Chemical compound NC1=CC=CC(Br)=C1 DHYHYLGCQVVLOQ-UHFFFAOYSA-N 0.000 description 2
- DLFVBJFMPXGRIB-UHFFFAOYSA-N Acetamide Chemical compound CC(N)=O DLFVBJFMPXGRIB-UHFFFAOYSA-N 0.000 description 2
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 2
- ROSDSFDQCJNGOL-UHFFFAOYSA-N Dimethylamine Chemical compound CNC ROSDSFDQCJNGOL-UHFFFAOYSA-N 0.000 description 2
- 102000004877 Insulin Human genes 0.000 description 2
- 108090001061 Insulin Proteins 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 2
- 159000000021 acetate salts Chemical class 0.000 description 2
- 150000001242 acetic acid derivatives Chemical class 0.000 description 2
- 150000001408 amides Chemical class 0.000 description 2
- 230000001093 anti-cancer Effects 0.000 description 2
- 229940124650 anti-cancer therapies Drugs 0.000 description 2
- 238000011319 anticancer therapy Methods 0.000 description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
- HONIICLYMWZJFZ-UHFFFAOYSA-N azetidine Chemical compound C1CNC1 HONIICLYMWZJFZ-UHFFFAOYSA-N 0.000 description 2
- 125000002619 bicyclic group Chemical group 0.000 description 2
- 230000003833 cell viability Effects 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 210000004748 cultured cell Anatomy 0.000 description 2
- 239000003405 delayed action preparation Substances 0.000 description 2
- 125000004663 dialkyl amino group Chemical group 0.000 description 2
- JQVDAXLFBXTEQA-UHFFFAOYSA-N dibutylamine Chemical compound CCCCNCCCC JQVDAXLFBXTEQA-UHFFFAOYSA-N 0.000 description 2
- 230000004069 differentiation Effects 0.000 description 2
- QKIUAMUSENSFQQ-UHFFFAOYSA-N dimethylazanide Chemical compound C[N-]C QKIUAMUSENSFQQ-UHFFFAOYSA-N 0.000 description 2
- 208000035475 disorder Diseases 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 239000003937 drug carrier Substances 0.000 description 2
- 230000012010 growth Effects 0.000 description 2
- 125000001072 heteroaryl group Chemical group 0.000 description 2
- 125000005842 heteroatom Chemical group 0.000 description 2
- JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 description 2
- 125000002883 imidazolyl group Chemical group 0.000 description 2
- 125000001041 indolyl group Chemical group 0.000 description 2
- 229940125396 insulin Drugs 0.000 description 2
- 239000003456 ion exchange resin Substances 0.000 description 2
- 229920003303 ion-exchange polymer Polymers 0.000 description 2
- 239000000314 lubricant Substances 0.000 description 2
- 150000007522 mineralic acids Chemical class 0.000 description 2
- 125000002950 monocyclic group Chemical group 0.000 description 2
- 150000007524 organic acids Chemical class 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- 239000001301 oxygen Chemical group 0.000 description 2
- 229960003243 phenformin Drugs 0.000 description 2
- ICFJFFQQTFMIBG-UHFFFAOYSA-N phenformin Chemical compound NC(=N)NC(=N)NCCC1=CC=CC=C1 ICFJFFQQTFMIBG-UHFFFAOYSA-N 0.000 description 2
- 238000010837 poor prognosis Methods 0.000 description 2
- 230000035755 proliferation Effects 0.000 description 2
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 2
- 125000003373 pyrazinyl group Chemical group 0.000 description 2
- 125000000168 pyrrolyl group Chemical group 0.000 description 2
- 230000035484 reaction time Effects 0.000 description 2
- BOLDJAUMGUJJKM-LSDHHAIUSA-N renifolin D Natural products CC(=C)[C@@H]1Cc2c(O)c(O)ccc2[C@H]1CC(=O)c3ccc(O)cc3O BOLDJAUMGUJJKM-LSDHHAIUSA-N 0.000 description 2
- 229930195734 saturated hydrocarbon Natural products 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 2
- 125000005420 sulfonamido group Chemical group S(=O)(=O)(N*)* 0.000 description 2
- 229910052717 sulfur Chemical group 0.000 description 2
- 239000011593 sulfur Chemical group 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 description 2
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 2
- 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 description 1
- PVOAHINGSUIXLS-UHFFFAOYSA-N 1-Methylpiperazine Chemical compound CN1CCNCC1 PVOAHINGSUIXLS-UHFFFAOYSA-N 0.000 description 1
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
- QCQCHGYLTSGIGX-GHXANHINSA-N 4-[[(3ar,5ar,5br,7ar,9s,11ar,11br,13as)-5a,5b,8,8,11a-pentamethyl-3a-[(5-methylpyridine-3-carbonyl)amino]-2-oxo-1-propan-2-yl-4,5,6,7,7a,9,10,11,11b,12,13,13a-dodecahydro-3h-cyclopenta[a]chrysen-9-yl]oxy]-2,2-dimethyl-4-oxobutanoic acid Chemical compound N([C@@]12CC[C@@]3(C)[C@]4(C)CC[C@H]5C(C)(C)[C@@H](OC(=O)CC(C)(C)C(O)=O)CC[C@]5(C)[C@H]4CC[C@@H]3C1=C(C(C2)=O)C(C)C)C(=O)C1=CN=CC(C)=C1 QCQCHGYLTSGIGX-GHXANHINSA-N 0.000 description 1
- FBSCDQWBTPUPJI-UHFFFAOYSA-N 4-[[amino-[(Z)-[amino(piperidin-1-yl)methylidene]amino]methylidene]amino]benzenesulfonic acid hydrochloride Chemical compound Cl.N=C(NC(NC1=CC=C(C=C1)S(=O)(=O)O)=N)N1CCCCC1 FBSCDQWBTPUPJI-UHFFFAOYSA-N 0.000 description 1
- 102100022900 Actin, cytoplasmic 1 Human genes 0.000 description 1
- 108010085238 Actins Proteins 0.000 description 1
- 229940123208 Biguanide Drugs 0.000 description 1
- XNCOSPRUTUOJCJ-UHFFFAOYSA-N Biguanide Chemical compound NC(N)=NC(N)=N XNCOSPRUTUOJCJ-UHFFFAOYSA-N 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- ZFZCYPKQTHKXRJ-UHFFFAOYSA-N C(C)(=O)O.FC(C1=CC=C(C=C1)NC(=N)NC(=N)N1CCCCC1)(F)F Chemical compound C(C)(=O)O.FC(C1=CC=C(C=C1)NC(=N)NC(=N)N1CCCCC1)(F)F ZFZCYPKQTHKXRJ-UHFFFAOYSA-N 0.000 description 1
- 102000000905 Cadherin Human genes 0.000 description 1
- 108050007957 Cadherin Proteins 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 102100025064 Cellular tumor antigen p53 Human genes 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000015303 Fatty Acid Synthases Human genes 0.000 description 1
- 108010039731 Fatty Acid Synthases Proteins 0.000 description 1
- 241000287828 Gallus gallus Species 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101000721661 Homo sapiens Cellular tumor antigen p53 Proteins 0.000 description 1
- 101000785626 Homo sapiens Zinc finger E-box-binding homeobox 1 Proteins 0.000 description 1
- 206010060378 Hyperinsulinaemia Diseases 0.000 description 1
- 208000013016 Hypoglycemia Diseases 0.000 description 1
- 206010021143 Hypoxia Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 102000008135 Mechanistic Target of Rapamycin Complex 1 Human genes 0.000 description 1
- 108010035196 Mechanistic Target of Rapamycin Complex 1 Proteins 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- FFNIUHZNUOZRTL-UHFFFAOYSA-N N'-(N'-phenylcarbamimidoyl)piperidine-1-carboximidamide hydrochloride Chemical compound Cl.N\C(\N=C(/N)N1CCCCC1)=N/c1ccccc1 FFNIUHZNUOZRTL-UHFFFAOYSA-N 0.000 description 1
- FXBRTIGTIZMMSW-UHFFFAOYSA-N N'-[N'-(2,4,6-trifluorophenyl)carbamimidoyl]piperidine-1-carboximidamide hydrochloride Chemical compound Cl.FC1=C(C(=CC(=C1)F)F)NC(=N)NC(=N)N1CCCCC1 FXBRTIGTIZMMSW-UHFFFAOYSA-N 0.000 description 1
- YJLSYMSIMNFFFS-UHFFFAOYSA-N N'-[N'-(2,4-dichlorophenyl)carbamimidoyl]piperidine-1-carboximidamide hydrochloride Chemical compound Cl.ClC1=C(C=CC(=C1)Cl)NC(=N)NC(=N)N1CCCCC1 YJLSYMSIMNFFFS-UHFFFAOYSA-N 0.000 description 1
- NGYCHKSWFFHLRR-UHFFFAOYSA-N N'-[N'-(2,4-difluorophenyl)carbamimidoyl]piperidine-1-carboximidamide hydrochloride Chemical compound Cl.FC1=C(C=CC(=C1)F)NC(=N)NC(=N)N1CCCCC1 NGYCHKSWFFHLRR-UHFFFAOYSA-N 0.000 description 1
- FJRCWRKLFZZJDD-UHFFFAOYSA-N N'-[N'-(2-fluorophenyl)carbamimidoyl]piperidine-1-carboximidamide hydrochloride Chemical compound Cl.FC1=C(C=CC=C1)NC(=N)NC(=N)N1CCCCC1 FJRCWRKLFZZJDD-UHFFFAOYSA-N 0.000 description 1
- MQNQDLKQLSSNES-UHFFFAOYSA-N N'-[N'-(3,4,5-trifluorophenyl)carbamimidoyl]piperidine-1-carboximidamide hydrochloride Chemical compound Cl.FC=1C=C(C=C(C1F)F)NC(=N)NC(=N)N1CCCCC1 MQNQDLKQLSSNES-UHFFFAOYSA-N 0.000 description 1
- VESRILOPQWXJHR-UHFFFAOYSA-N N'-[N'-(3,4-dichlorophenyl)carbamimidoyl]piperidine-1-carboximidamide hydrochloride Chemical compound Cl.ClC=1C=C(C=CC1Cl)NC(=N)NC(=N)N1CCCCC1 VESRILOPQWXJHR-UHFFFAOYSA-N 0.000 description 1
- DHGSBVDPWSNAEM-UHFFFAOYSA-N N'-[N'-(3,4-dichlorophenyl)carbamimidoyl]pyrrolidine-1-carboximidamide hydrochloride Chemical compound Cl.ClC=1C=C(C=CC1Cl)NC(=N)NC(=N)N1CCCC1 DHGSBVDPWSNAEM-UHFFFAOYSA-N 0.000 description 1
- USNUNNRMPJEMON-UHFFFAOYSA-N N'-[N'-(3,4-difluorophenyl)carbamimidoyl]piperidine-1-carboximidamide hydrochloride Chemical compound Cl.FC=1C=C(C=CC1F)NC(=N)NC(=N)N1CCCCC1 USNUNNRMPJEMON-UHFFFAOYSA-N 0.000 description 1
- DMLBBZYWAINJGC-UHFFFAOYSA-N N'-[N'-(3,5-dichlorophenyl)carbamimidoyl]piperidine-1-carboximidamide hydrochloride Chemical compound Cl.ClC=1C=C(C=C(C1)Cl)NC(=N)NC(=N)N1CCCCC1 DMLBBZYWAINJGC-UHFFFAOYSA-N 0.000 description 1
- DUMNVIXJURYMDU-UHFFFAOYSA-N N'-[N'-(3,5-difluorophenyl)carbamimidoyl]piperidine-1-carboximidamide hydrochloride Chemical compound Cl.FC=1C=C(C=C(C1)F)NC(=N)NC(=N)N1CCCCC1 DUMNVIXJURYMDU-UHFFFAOYSA-N 0.000 description 1
- OKVLBJZJXQUCBJ-UHFFFAOYSA-N N'-[N'-(3,5-dimethoxyphenyl)carbamimidoyl]piperidine-1-carboximidamide hydrochloride Chemical compound Cl.COC=1C=C(C=C(C1)OC)NC(=N)NC(=N)N1CCCCC1 OKVLBJZJXQUCBJ-UHFFFAOYSA-N 0.000 description 1
- VJIXLJXUMROMFZ-UHFFFAOYSA-N N'-[N'-(3-aminophenyl)carbamimidoyl]piperidine-1-carboximidamide hydrochloride Chemical compound Cl.NC=1C=C(C=CC1)NC(=N)NC(=N)N1CCCCC1 VJIXLJXUMROMFZ-UHFFFAOYSA-N 0.000 description 1
- ALXSNJCDPMUHBF-UHFFFAOYSA-N N'-[N'-(3-bromophenyl)carbamimidoyl]morpholine-4-carboximidamide hydrochloride Chemical compound Cl.BrC=1C=C(C=CC1)NC(=N)NC(=N)N1CCOCC1 ALXSNJCDPMUHBF-UHFFFAOYSA-N 0.000 description 1
- CZIQOPWVCPHQJT-UHFFFAOYSA-N N'-[N'-(3-bromophenyl)carbamimidoyl]piperidine-1-carboximidamide hydrochloride Chemical compound Cl.BrC=1C=C(C=CC1)NC(=N)NC(=N)N1CCCCC1 CZIQOPWVCPHQJT-UHFFFAOYSA-N 0.000 description 1
- IJVOJDBVKZVIHB-UHFFFAOYSA-N N'-[N'-(3-chlorophenyl)carbamimidoyl]azepane-1-carboximidamide hydrochloride Chemical compound Cl.ClC=1C=C(C=CC1)NC(=N)NC(=N)N1CCCCCC1 IJVOJDBVKZVIHB-UHFFFAOYSA-N 0.000 description 1
- CWAKYMAELYUJDD-UHFFFAOYSA-N N'-[N'-(3-chlorophenyl)carbamimidoyl]piperidine-1-carboximidamide hydrochloride Chemical compound Cl.ClC=1C=C(C=CC1)NC(=N)NC(=N)N1CCCCC1 CWAKYMAELYUJDD-UHFFFAOYSA-N 0.000 description 1
- UDQHSCASWOWXJT-UHFFFAOYSA-N N'-[N'-(3-chlorophenyl)carbamimidoyl]pyrrolidine-1-carboximidamide hydrochloride Chemical compound Cl.ClC=1C=C(C=CC1)NC(=N)NC(=N)N1CCCC1 UDQHSCASWOWXJT-UHFFFAOYSA-N 0.000 description 1
- OWCRHYRTGSWFAD-UHFFFAOYSA-N N'-[N'-(3-ethylphenyl)carbamimidoyl]piperidine-1-carboximidamide hydrochloride Chemical compound Cl.C(C)C=1C=C(C=CC1)NC(=N)NC(=N)N1CCCCC1 OWCRHYRTGSWFAD-UHFFFAOYSA-N 0.000 description 1
- POYUHUVIRFEYLA-UHFFFAOYSA-N N'-[N'-(3-fluorophenyl)carbamimidoyl]piperidine-1-carboximidamide hydrochloride Chemical compound Cl.FC=1C=C(C=CC1)NC(=N)NC(=N)N1CCCCC1 POYUHUVIRFEYLA-UHFFFAOYSA-N 0.000 description 1
- IDUMLGDZOSBQPC-UHFFFAOYSA-N N'-[N'-(3-hydroxyphenyl)carbamimidoyl]piperidine-1-carboximidamide hydrochloride Chemical compound Cl.OC=1C=C(C=CC1)NC(=N)NC(=N)N1CCCCC1 IDUMLGDZOSBQPC-UHFFFAOYSA-N 0.000 description 1
- VRVUHWLSGCCYQO-UHFFFAOYSA-N N'-[N'-(3-methoxyphenyl)carbamimidoyl]piperidine-1-carboximidamide hydrochloride Chemical compound Cl.COC=1C=C(C=CC1)NC(=N)NC(=N)N1CCCCC1 VRVUHWLSGCCYQO-UHFFFAOYSA-N 0.000 description 1
- CWMVABXGCZCKCG-UHFFFAOYSA-N N'-[N'-(4-chlorophenyl)carbamimidoyl]pyrrolidine-1-carboximidamide hydrochloride Chemical compound Cl.ClC1=CC=C(C=C1)NC(=N)NC(=N)N1CCCC1 CWMVABXGCZCKCG-UHFFFAOYSA-N 0.000 description 1
- DSGMJNDHWHKDIP-UHFFFAOYSA-N N'-[N'-(4-fluorophenyl)carbamimidoyl]piperidine-1-carboximidamide hydrochloride Chemical compound Cl.FC1=CC=C(C=C1)NC(=N)NC(=N)N1CCCCC1 DSGMJNDHWHKDIP-UHFFFAOYSA-N 0.000 description 1
- YOPPOSUVUNMGBV-UHFFFAOYSA-N N'-[N'-(4-methylsulfanylphenyl)carbamimidoyl]piperidine-1-carboximidamide hydrochloride Chemical compound Cl.CSC1=CC=C(C=C1)NC(=N)NC(=N)N1CCCCC1 YOPPOSUVUNMGBV-UHFFFAOYSA-N 0.000 description 1
- UVFFCNRJEFVMPQ-UHFFFAOYSA-N N'-[N'-(4-sulfamoylphenyl)carbamimidoyl]piperidine-1-carboximidamide hydrochloride Chemical compound Cl.S(N)(=O)(=O)C1=CC=C(C=C1)NC(=N)NC(=N)N1CCCCC1 UVFFCNRJEFVMPQ-UHFFFAOYSA-N 0.000 description 1
- MRTBIMUHSUOXAJ-UHFFFAOYSA-N N'-[N'-[3-(difluoromethoxy)phenyl]carbamimidoyl]piperidine-1-carboximidamide hydrochloride Chemical compound Cl.FC(OC=1C=C(C=CC1)NC(=N)NC(=N)N1CCCCC1)F MRTBIMUHSUOXAJ-UHFFFAOYSA-N 0.000 description 1
- YJJRWVVZTPRRST-UHFFFAOYSA-N N'-[N'-[3-(hydroxymethyl)phenyl]carbamimidoyl]piperidine-1-carboximidamide hydrochloride Chemical compound Cl.OCC=1C=C(C=CC1)NC(=N)NC(=N)N1CCCCC1 YJJRWVVZTPRRST-UHFFFAOYSA-N 0.000 description 1
- AETZUTUTFFSMND-UHFFFAOYSA-N N'-[N'-[3-(methanesulfonamido)phenyl]carbamimidoyl]piperidine-1-carboximidamide hydrochloride Chemical compound Cl.CS(=O)(=O)NC=1C=C(C=CC1)NC(=N)NC(=N)N1CCCCC1 AETZUTUTFFSMND-UHFFFAOYSA-N 0.000 description 1
- KCLKUNULZUUQMG-UHFFFAOYSA-N N'-[N'-[3-(trifluoromethoxy)phenyl]carbamimidoyl]piperidine-1-carboximidamide hydrochloride Chemical compound Cl.FC(OC=1C=C(C=CC1)NC(=N)NC(=N)N1CCCCC1)(F)F KCLKUNULZUUQMG-UHFFFAOYSA-N 0.000 description 1
- VETIHZJKLKUIGT-UHFFFAOYSA-N N'-[N'-[3-(trifluoromethoxy)phenyl]carbamimidoyl]pyrrolidine-1-carboximidamide hydrochloride Chemical compound Cl.FC(OC=1C=C(C=CC1)NC(=N)NC(=N)N1CCCC1)(F)F VETIHZJKLKUIGT-UHFFFAOYSA-N 0.000 description 1
- ANDIBXXKBWLNOV-UHFFFAOYSA-N N'-[N'-[3-(trifluoromethyl)phenyl]carbamimidoyl]piperidine-1-carboximidamide hydrochloride Chemical compound Cl.FC(C=1C=C(C=CC1)NC(=N)NC(=N)N1CCCCC1)(F)F ANDIBXXKBWLNOV-UHFFFAOYSA-N 0.000 description 1
- HJBMQYQAAHSODI-UHFFFAOYSA-N N'-[N'-[3-(trifluoromethyl)phenyl]carbamimidoyl]pyrrolidine-1-carboximidamide hydrochloride Chemical compound Cl.FC(C=1C=C(C=CC1)NC(=N)NC(=N)N1CCCC1)(F)F HJBMQYQAAHSODI-UHFFFAOYSA-N 0.000 description 1
- SQDKJAHRTINMBC-UHFFFAOYSA-N N'-[N'-[3-bromo-5-(trifluoromethoxy)phenyl]carbamimidoyl]piperidine-1-carboximidamide hydrochloride Chemical compound Cl.BrC=1C=C(C=C(C1)OC(F)(F)F)NC(=N)NC(=N)N1CCCCC1 SQDKJAHRTINMBC-UHFFFAOYSA-N 0.000 description 1
- CDRCPSRJFVNNGC-UHFFFAOYSA-N N'-[N'-[3-bromo-5-(trifluoromethoxy)phenyl]carbamimidoyl]pyrrolidine-1-carboximidamide hydrochloride Chemical compound Cl.BrC=1C=C(C=C(C1)OC(F)(F)F)NC(=N)NC(=N)N1CCCC1 CDRCPSRJFVNNGC-UHFFFAOYSA-N 0.000 description 1
- BTEVZHWIAKEUQM-UHFFFAOYSA-N N'-[N'-[3-chloro-4-(trifluoromethoxy)phenyl]carbamimidoyl]azetidine-1-carboximidamide hydrochloride Chemical compound Cl.ClC=1C=C(C=CC1OC(F)(F)F)NC(=N)NC(=N)N1CCC1 BTEVZHWIAKEUQM-UHFFFAOYSA-N 0.000 description 1
- ACMAQBRIYQTBBP-UHFFFAOYSA-N N'-[N'-[3-chloro-4-(trifluoromethoxy)phenyl]carbamimidoyl]piperidine-1-carboximidamide hydrochloride Chemical compound Cl.ClC=1C=C(C=CC1OC(F)(F)F)NC(=N)NC(=N)N1CCCCC1 ACMAQBRIYQTBBP-UHFFFAOYSA-N 0.000 description 1
- MCQCWQDLODWFPD-UHFFFAOYSA-N N'-[N'-[3-chloro-5-(trifluoromethoxy)phenyl]carbamimidoyl]piperidine-1-carboximidamide hydrochloride Chemical compound Cl.ClC=1C=C(C=C(C1)OC(F)(F)F)NC(=N)NC(=N)N1CCCCC1 MCQCWQDLODWFPD-UHFFFAOYSA-N 0.000 description 1
- NHPDWYBBWFHRGJ-UHFFFAOYSA-N N'-[N'-[3-fluoro-4-(trifluoromethoxy)phenyl]carbamimidoyl]azetidine-1-carboximidamide hydrochloride Chemical compound Cl.FC=1C=C(C=CC1OC(F)(F)F)NC(=N)NC(=N)N1CCC1 NHPDWYBBWFHRGJ-UHFFFAOYSA-N 0.000 description 1
- QEPBZKZIQUQENE-UHFFFAOYSA-N N'-[N'-[3-fluoro-4-(trifluoromethoxy)phenyl]carbamimidoyl]piperidine-1-carboximidamide hydrochloride Chemical compound Cl.FC=1C=C(C=CC1OC(F)(F)F)NC(=N)NC(=N)N1CCCCC1 QEPBZKZIQUQENE-UHFFFAOYSA-N 0.000 description 1
- TVUNBKQIULEKDW-UHFFFAOYSA-N N'-[N'-[3-fluoro-4-(trifluoromethoxy)phenyl]carbamimidoyl]pyrrolidine-1-carboximidamide hydrochloride Chemical compound Cl.FC=1C=C(C=CC1OC(F)(F)F)NC(=N)NC(=N)N1CCCC1 TVUNBKQIULEKDW-UHFFFAOYSA-N 0.000 description 1
- KBLYDLBNBJGBAZ-UHFFFAOYSA-N N'-[N'-[3-fluoro-4-(trifluoromethyl)phenyl]carbamimidoyl]piperidine-1-carboximidamide hydrochloride Chemical compound Cl.FC=1C=C(C=CC1C(F)(F)F)NC(=N)NC(=N)N1CCCCC1 KBLYDLBNBJGBAZ-UHFFFAOYSA-N 0.000 description 1
- ZVRMSLCDBLPNSC-UHFFFAOYSA-N N'-[N'-[4-(2H-tetrazol-5-yl)phenyl]carbamimidoyl]piperidine-1-carboximidamide hydrochloride Chemical compound Cl.N1N=NN=C1C1=CC=C(C=C1)NC(=N)NC(=N)N1CCCCC1 ZVRMSLCDBLPNSC-UHFFFAOYSA-N 0.000 description 1
- OYCAYJXHEDALFU-UHFFFAOYSA-N N'-[N'-[4-(dimethylamino)phenyl]carbamimidoyl]piperidine-1-carboximidamide hydrochloride Chemical compound Cl.CN(C1=CC=C(C=C1)NC(=N)NC(=N)N1CCCCC1)C OYCAYJXHEDALFU-UHFFFAOYSA-N 0.000 description 1
- OTJBYEXGENHSEN-UHFFFAOYSA-N N'-[N'-[4-(trifluoromethoxy)phenyl]carbamimidoyl]azetidine-1-carboximidamide hydrochloride Chemical compound Cl.FC(OC1=CC=C(C=C1)NC(=N)NC(=N)N1CCC1)(F)F OTJBYEXGENHSEN-UHFFFAOYSA-N 0.000 description 1
- KXHSOZJWWRQXRA-UHFFFAOYSA-N N'-[N'-[4-(trifluoromethoxy)phenyl]carbamimidoyl]morpholine-4-carboximidamide hydrochloride Chemical compound Cl.FC(OC1=CC=C(C=C1)NC(=N)NC(=N)N1CCOCC1)(F)F KXHSOZJWWRQXRA-UHFFFAOYSA-N 0.000 description 1
- XOCZPAVVLRHKFF-UHFFFAOYSA-N N'-[N'-[4-(trifluoromethoxy)phenyl]carbamimidoyl]piperidine-1-carboximidamide hydrochloride Chemical compound Cl.FC(OC1=CC=C(C=C1)NC(=N)NC(=N)N1CCCCC1)(F)F XOCZPAVVLRHKFF-UHFFFAOYSA-N 0.000 description 1
- FSEAYPJRYNBFTN-UHFFFAOYSA-N N'-[N'-[4-(trifluoromethoxy)phenyl]carbamimidoyl]pyrrolidine-1-carboximidamide hydrochloride Chemical compound Cl.FC(OC1=CC=C(C=C1)NC(=N)NC(=N)N1CCCC1)(F)F FSEAYPJRYNBFTN-UHFFFAOYSA-N 0.000 description 1
- GXGAVHQOKFWTGT-UHFFFAOYSA-N N'-[N'-[4-(trifluoromethyl)phenyl]carbamimidoyl]azetidine-1-carboximidamide hydrochloride Chemical compound Cl.FC(C1=CC=C(C=C1)NC(=N)NC(=N)N1CCC1)(F)F GXGAVHQOKFWTGT-UHFFFAOYSA-N 0.000 description 1
- ZUZHIQAAOZYURA-UHFFFAOYSA-N N'-[N'-[4-(trifluoromethyl)phenyl]carbamimidoyl]piperidine-1-carboximidamide hydrochloride Chemical compound Cl.FC(C1=CC=C(C=C1)NC(=N)NC(=N)N1CCCCC1)(F)F ZUZHIQAAOZYURA-UHFFFAOYSA-N 0.000 description 1
- LAHUETQIQSXHFG-UHFFFAOYSA-N N'-[N'-[4-(trifluoromethyl)phenyl]carbamimidoyl]pyrrolidine-1-carboximidamide hydrochloride Chemical compound Cl.FC(C1=CC=C(C=C1)NC(=N)NC(=N)N1CCCC1)(F)F LAHUETQIQSXHFG-UHFFFAOYSA-N 0.000 description 1
- WKHQSUJTOPKLOW-UHFFFAOYSA-N N'-[N'-[4-chloro-3-(trifluoromethoxy)phenyl]carbamimidoyl]piperidine-1-carboximidamide hydrochloride Chemical compound Cl.ClC1=C(C=C(C=C1)NC(=N)NC(=N)N1CCCCC1)OC(F)(F)F WKHQSUJTOPKLOW-UHFFFAOYSA-N 0.000 description 1
- OFUFCNFNSDLCOJ-UHFFFAOYSA-N N'-[N'-[4-chloro-3-(trifluoromethyl)phenyl]carbamimidoyl]piperidine-1-carboximidamide hydrochloride Chemical compound Cl.ClC1=C(C=C(C=C1)NC(=N)NC(=N)N1CCCCC1)C(F)(F)F OFUFCNFNSDLCOJ-UHFFFAOYSA-N 0.000 description 1
- NSNNHRCOZBDJSC-UHFFFAOYSA-N N'-[N'-[4-fluoro-3-(trifluoromethoxy)phenyl]carbamimidoyl]piperidine-1-carboximidamide hydrochloride Chemical compound Cl.FC1=C(C=C(C=C1)NC(=N)NC(=N)N1CCCCC1)OC(F)(F)F NSNNHRCOZBDJSC-UHFFFAOYSA-N 0.000 description 1
- YZWYQXVNLLXAEQ-UHFFFAOYSA-N N'-[N'-[4-fluoro-3-(trifluoromethyl)phenyl]carbamimidoyl]piperidine-1-carboximidamide hydrochloride Chemical compound Cl.FC1=C(C=C(C=C1)NC(=N)NC(=N)N1CCCCC1)C(F)(F)F YZWYQXVNLLXAEQ-UHFFFAOYSA-N 0.000 description 1
- KMBADQSSJSMGAQ-UHFFFAOYSA-N N-[3-[[amino-[(Z)-[amino(piperidin-1-yl)methylidene]amino]methylidene]amino]phenyl]acetamide hydrochloride Chemical compound Cl.N=C(NC(NC=1C=C(C=CC1)NC(C)=O)=N)N1CCCCC1 KMBADQSSJSMGAQ-UHFFFAOYSA-N 0.000 description 1
- RSOBWZSWKHHUAS-UHFFFAOYSA-N N-[4-[[amino-[(Z)-[amino(piperidin-1-yl)methylidene]amino]methylidene]amino]phenyl]acetamide hydrochloride Chemical compound Cl.N=C(NC(NC1=CC=C(C=C1)NC(C)=O)=N)N1CCCCC1 RSOBWZSWKHHUAS-UHFFFAOYSA-N 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 241000139306 Platt Species 0.000 description 1
- 241000282405 Pongo abelii Species 0.000 description 1
- 102100024908 Ribosomal protein S6 kinase beta-1 Human genes 0.000 description 1
- 101710108924 Ribosomal protein S6 kinase beta-1 Proteins 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- 102000013530 TOR Serine-Threonine Kinases Human genes 0.000 description 1
- 108010065917 TOR Serine-Threonine Kinases Proteins 0.000 description 1
- 102100026457 Zinc finger E-box-binding homeobox 1 Human genes 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- AGFDCTOLSXWRDZ-UHFFFAOYSA-N acetic acid N'-[N'-[4-(trifluoromethoxy)phenyl]carbamimidoyl]pyrrolidine-1-carboximidamide Chemical compound C(C)(=O)O.N1(CCCC1)C(NC(NC1=CC=C(C=C1)OC(F)(F)F)=N)=N AGFDCTOLSXWRDZ-UHFFFAOYSA-N 0.000 description 1
- UDMBCSSLTHHNCD-KQYNXXCUSA-N adenosine 5'-monophosphate Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@H]1O UDMBCSSLTHHNCD-KQYNXXCUSA-N 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 125000003368 amide group Chemical group 0.000 description 1
- 230000001195 anabolic effect Effects 0.000 description 1
- 239000000883 anti-obesity agent Substances 0.000 description 1
- 229940125710 antiobesity agent Drugs 0.000 description 1
- 230000004900 autophagic degradation Effects 0.000 description 1
- ZSIQJIWKELUFRJ-UHFFFAOYSA-N azepane Chemical compound C1CCCNCC1 ZSIQJIWKELUFRJ-UHFFFAOYSA-N 0.000 description 1
- 125000004069 aziridinyl group Chemical group 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 125000003785 benzimidazolyl group Chemical group N1=C(NC2=C1C=CC=C2)* 0.000 description 1
- 125000000499 benzofuranyl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 description 1
- 229960004365 benzoic acid Drugs 0.000 description 1
- 125000001164 benzothiazolyl group Chemical group S1C(=NC2=C1C=CC=C2)* 0.000 description 1
- 125000004196 benzothienyl group Chemical group S1C(=CC2=C1C=CC=C2)* 0.000 description 1
- 125000004541 benzoxazolyl group Chemical group O1C(=NC2=C1C=CC=C2)* 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000008033 biological extinction Effects 0.000 description 1
- 125000001246 bromo group Chemical group Br* 0.000 description 1
- DNSISZSEWVHGLH-UHFFFAOYSA-N butanamide Chemical compound CCCC(N)=O DNSISZSEWVHGLH-UHFFFAOYSA-N 0.000 description 1
- 230000005907 cancer growth Effects 0.000 description 1
- 125000003739 carbamimidoyl group Chemical group C(N)(=N)* 0.000 description 1
- 125000000609 carbazolyl group Chemical group C1(=CC=CC=2C3=CC=CC=C3NC12)* 0.000 description 1
- 239000008004 cell lysis buffer Substances 0.000 description 1
- 230000019522 cellular metabolic process Effects 0.000 description 1
- 229920001429 chelating resin Polymers 0.000 description 1
- 239000007806 chemical reaction intermediate Substances 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 235000013330 chicken meat Nutrition 0.000 description 1
- 125000001309 chloro group Chemical group Cl* 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 210000004351 coronary vessel Anatomy 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 229940009976 deoxycholate Drugs 0.000 description 1
- KXGVEGMKQFWNSR-LLQZFEROSA-N deoxycholic acid Chemical compound C([C@H]1CC2)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 KXGVEGMKQFWNSR-LLQZFEROSA-N 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- HPNMFZURTQLUMO-UHFFFAOYSA-N diethylamine Chemical compound CCNCC HPNMFZURTQLUMO-UHFFFAOYSA-N 0.000 description 1
- WEHWNAOGRSTTBQ-UHFFFAOYSA-N dipropylamine Chemical compound CCCNCCC WEHWNAOGRSTTBQ-UHFFFAOYSA-N 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 238000012377 drug delivery Methods 0.000 description 1
- 230000019439 energy homeostasis Effects 0.000 description 1
- 230000037149 energy metabolism Effects 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- DEFVIWRASFVYLL-UHFFFAOYSA-N ethylene glycol bis(2-aminoethyl)tetraacetic acid Chemical compound OC(=O)CN(CC(O)=O)CCOCCOCCN(CC(O)=O)CC(O)=O DEFVIWRASFVYLL-UHFFFAOYSA-N 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 125000001153 fluoro group Chemical group F* 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 125000002541 furyl group Chemical group 0.000 description 1
- 230000009229 glucose formation Effects 0.000 description 1
- 229960004275 glycolic acid Drugs 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 229940093915 gynecological organic acid Drugs 0.000 description 1
- 230000003862 health status Effects 0.000 description 1
- 229960000890 hydrocortisone Drugs 0.000 description 1
- 230000003451 hyperinsulinaemic effect Effects 0.000 description 1
- 201000008980 hyperinsulinism Diseases 0.000 description 1
- 230000002218 hypoglycaemic effect Effects 0.000 description 1
- 208000018875 hypoxemia Diseases 0.000 description 1
- 125000003387 indolinyl group Chemical group N1(CCC2=CC=CC=C12)* 0.000 description 1
- 125000003406 indolizinyl group Chemical group C=1(C=CN2C=CC=CC12)* 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 125000002346 iodo group Chemical group I* 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 125000001972 isopentyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 125000002183 isoquinolinyl group Chemical group C1(=NC=CC2=CC=CC=C12)* 0.000 description 1
- 125000001786 isothiazolyl group Chemical group 0.000 description 1
- 125000000842 isoxazolyl group Chemical group 0.000 description 1
- 208000006443 lactic acidosis Diseases 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 230000037353 metabolic pathway Effects 0.000 description 1
- 230000001394 metastastic effect Effects 0.000 description 1
- 206010061289 metastatic neoplasm Diseases 0.000 description 1
- FJQXCDYVZAHXNS-UHFFFAOYSA-N methadone hydrochloride Chemical compound Cl.C=1C=CC=CC=1C(CC(C)N(C)C)(C(=O)CC)C1=CC=CC=C1 FJQXCDYVZAHXNS-UHFFFAOYSA-N 0.000 description 1
- HNQIVZYLYMDVSB-UHFFFAOYSA-N methanesulfonimidic acid Chemical compound CS(N)(=O)=O HNQIVZYLYMDVSB-UHFFFAOYSA-N 0.000 description 1
- 230000005787 mitochondrial ATP synthesis coupled electron transport Effects 0.000 description 1
- 239000011259 mixed solution Substances 0.000 description 1
- 230000004899 motility Effects 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- IOGYTDMKOJZROG-UHFFFAOYSA-N n'-[n'-(3,4-difluorophenyl)carbamimidoyl]piperidine-1-carboximidamide Chemical compound C=1C=C(F)C(F)=CC=1N=C(N)\N=C(/N)N1CCCCC1 IOGYTDMKOJZROG-UHFFFAOYSA-N 0.000 description 1
- OJBBLVVDOJOAJT-UHFFFAOYSA-N n'-[n'-(4-chlorophenyl)carbamimidoyl]piperidine-1-carboximidamide;hydrochloride Chemical compound Cl.C=1C=C(Cl)C=CC=1N=C(N)\N=C(/N)N1CCCCC1 OJBBLVVDOJOAJT-UHFFFAOYSA-N 0.000 description 1
- VMGAPWLDMVPYIA-HIDZBRGKSA-N n'-amino-n-iminomethanimidamide Chemical compound N\N=C\N=N VMGAPWLDMVPYIA-HIDZBRGKSA-N 0.000 description 1
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000003136 n-heptyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000001280 n-hexyl group Chemical group C(CCCCC)* 0.000 description 1
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 125000002347 octyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 125000002971 oxazolyl group Chemical group 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 239000002831 pharmacologic agent Substances 0.000 description 1
- 230000000865 phosphorylative effect Effects 0.000 description 1
- 125000004592 phthalazinyl group Chemical group C1(=NN=CC2=CC=CC=C12)* 0.000 description 1
- AGVOIHMRBFEGBE-UHFFFAOYSA-N piperidin-1-ium-1-carboximidamide;chloride Chemical compound Cl.NC(=N)N1CCCCC1 AGVOIHMRBFEGBE-UHFFFAOYSA-N 0.000 description 1
- 125000005936 piperidyl group Chemical group 0.000 description 1
- YPCZZGDKIBPATR-UHFFFAOYSA-N potassium dicyanoazanide Chemical compound [K+].N#C[N-]C#N YPCZZGDKIBPATR-UHFFFAOYSA-N 0.000 description 1
- QLNJFJADRCOGBJ-UHFFFAOYSA-N propionamide Chemical compound CCC(N)=O QLNJFJADRCOGBJ-UHFFFAOYSA-N 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 125000003226 pyrazolyl group Chemical group 0.000 description 1
- 125000002098 pyridazinyl group Chemical group 0.000 description 1
- 125000000714 pyrimidinyl group Chemical group 0.000 description 1
- STXJBYRHIUKYKY-UHFFFAOYSA-N pyrrolidin-1-ium-1-carboximidamide;chloride Chemical compound Cl.NC(=N)N1CCCC1 STXJBYRHIUKYKY-UHFFFAOYSA-N 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- IXBPPZBJIFNGJJ-UHFFFAOYSA-N sodium;cyanoiminomethylideneazanide Chemical compound [Na+].N#C[N-]C#N IXBPPZBJIFNGJJ-UHFFFAOYSA-N 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000007939 sustained release tablet Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 125000000335 thiazolyl group Chemical group 0.000 description 1
- 125000000341 threoninyl group Chemical group [H]OC([H])(C([H])([H])[H])C([H])(N([H])[H])C(*)=O 0.000 description 1
- 125000004306 triazinyl group Chemical group 0.000 description 1
- 125000001425 triazolyl group Chemical group 0.000 description 1
- 125000004784 trichloromethoxy group Chemical group ClC(O*)(Cl)Cl 0.000 description 1
- 125000003866 trichloromethyl group Chemical group ClC(Cl)(Cl)* 0.000 description 1
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 1
- 230000004614 tumor growth Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
- C07D211/10—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with radicals containing only carbon and hydrogen atoms attached to ring carbon atoms
- C07D211/14—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with radicals containing only carbon and hydrogen atoms attached to ring carbon atoms with hydrocarbon or substituted hydrocarbon radicals attached to the ring nitrogen atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C279/00—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups
- C07C279/20—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups containing any of the groups, X being a hetero atom, Y being any atom, e.g. acylguanidines
- C07C279/24—Y being a hetero atom
- C07C279/26—X and Y being nitrogen atoms, i.e. biguanides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D205/00—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom
- C07D205/02—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings
- C07D205/04—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/06—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with radicals, containing only hydrogen and carbon atoms, attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D223/00—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom
- C07D223/02—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom not condensed with other rings
- C07D223/04—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom not condensed with other rings with only hydrogen atoms, halogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D257/00—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms
- C07D257/02—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D257/04—Five-membered rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
- C07D295/14—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/16—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
- C07D295/20—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carbonic acid, or sulfur or nitrogen analogues thereof
- C07D295/215—Radicals derived from nitrogen analogues of carbonic acid
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Obesity (AREA)
- Reproductive Health (AREA)
- Endocrinology (AREA)
- Oncology (AREA)
- Pregnancy & Childbirth (AREA)
- Neurology (AREA)
- Pain & Pain Management (AREA)
- Gastroenterology & Hepatology (AREA)
- Gynecology & Obstetrics (AREA)
- Emergency Medicine (AREA)
- Epidemiology (AREA)
- Child & Adolescent Psychology (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Description
nは1〜3の整数であり;
各R3はそれぞれ独立にヒドロキシ,C1-6アルキル,C1-6アルコキシ,C1-6アルキルチオ,アミノ,アセトアミド,アルキルスルホンアミド,テトラゾリル,スルホン酸及びスルファモイルからなる群から選ばれたものであり、C1-6アルキル又はC1-6アルコキシはそれぞれ独立にハロゲン又はヒドロキシから選ばれた少なくとも1つの置換基で置換されており、アミノは非置換であるかC1-6アルキルに置換されているか;又は
(2)R1及びR2はともに窒素に結合して、アゼチジニル又はアゼパニルを形成し;
nは0〜3の整数であり;
R3が複数ある場合、各R3はそれぞれ独立に水素,ハロゲン,C1-6アルキル及びC1-6アルコキシからなる群から選ばれたものであり、C1-6アルキル又はC1-6アルコキシはそれぞれ独立に非置換であるか、少なくともハロゲン又はヒドロキシから選ばれた少なくとも1つの置換基で置換されている。
R1及びR2はともに窒素に結合してピロリジニル又はピペリジニルを形成しても良く;
nは1又は2でも良く;
各R3はそれぞれ独立にハロアルキル及びハロアルコキシからなる群から選ばれたもので良い。
N-(N-m-トリルカルバムイミドイル)ピペリジン-1-カルボキシイミドアミド;
N-(N-(3-エチルフェニル)カルバムイミドイル)ピペリジン-1-カルボキシイミドアミド;
N-(N-(3-ヒドロキシフェニル)カルバムイミドイル)ピペリジン-1-カルボキシイミドアミド;
N-(N-(3-(ヒドロキシメチル)フェニル)カルバムイミドイル)ピペリジン-1-カルボキシイミドアミド;
N-(N-(3-フルオロフェニル)カルバムイミドイル)ピペリジン-1-カルボキシイミドアミド;
N-(N-(3-クロロフェニル)カルバムイミドイル)ピロリジン-1-カルボキシイミドアミド;
N-(N-(3-クロロフェニル)カルバムイミドイル)ピペリジン-1-カルボキシイミドアミド;
N-(N-(3-クロロフェニル)カルバムイミドイル)アゼパン-1-カルボキシイミドアミド;
N-(N-(3-(トリフルオロメチル)フェニル)カルバムイミドイル)ピロリジン-1-カルボキシイミドアミド;
N-(N-(3-(トリフルオロメチル)フェニル)カルバムイミドイル)ピペリジン-1-カルボキシイミドアミド;
N-(N-(4-(トリフルオロメチル)フェニル)カルバムイミドイル)アゼチジン-1-カルボキシイミドアミド;
N-(N-(4-(トリフルオロメチル)フェニル)カルバムイミドイル)ピペリジン-1-カルボキシイミドアミド;
N-(N-(3-(トリフルオロメトキシ)フェニル)カルバムイミドイル)ピロリジン-1-カルボキシイミドアミド;
N-(N-(3-(トリフルオロメトキシ)フェニル)カルバムイミドイル)ピペリジン-1-カルボキシイミドアミド;
N-(N-(3-(ジフルオロメトキシ)フェニル)カルバムイミドイル)ピペリジン-1-カルボキシイミドアミド;
N-(N-(4-(トリフルオロメトキシ)フェニル)カルバムイミドイル)アゼチジン-1-カルボキシイミドアミド;
N-(N-(4-(トリフルオロメトキシ)フェニル)カルバムイミドイル)ピペリジン-1-カルボキシイミドアミド;
4-メチル-N-(N-(4-(トリフルオロメトキシ)フェニル)カルバムイミドイル)ピペラジン-1-カルボキシイミドアミド;
N-(N-(3-アミノフェニル)カルバムイミドイル)ピペリジン-1-カルボキシイミドアミド;
N-(N-(4-(ジメチルアミノ)フェニル)カルバムイミドイル)ピペリジン-1-カルボキシイミドアミド;
N-(4-(3-(イミノ(ピペリジン-1-イル)メチル)グアニジノ)フェニル)アセトアミド;
N-(3-(3-(イミノ(ピペリジン-1-イル)メチル)グアニジノ)フェニル)アセトアミド;
N-(N-(4-(1H-テトラゾール-5-イル)フェニル)カルバムイミドイル)ピペリジン-1-カルボキシイミドアミド;
N-(N-(3-(メチルサルフォンアミド)フェニル)カルバムイミドイル)ピペリジン-1-カルボキシイミドアミド;
4-(3-(イミノ(ピペリジン-1-イル)メチル)グアニジノ)ベンゼンスルホン酸;
N-(N-(4-(メチルチオ)フェニル)カルバムイミドイル)ピペリジン-1-カルボキシイミドアミド;
N-(N-(4-スルファモイルフェニル)カルバムイミドイル)ピペリジン-1-カルボキシイミドアミド;
N-(N-(4-フルオロ-3-(トリフルオロメチル)フェニル)カルバムイミドイル)ピペリジン-1-カルボキシイミドアミド;
N-(N-(4-クロロ-3-(トリフルオロメチル)フェニル)カルバムイミドイル)ピペリジン-1-カルボキシイミドアミド;
N-(N-(3-フルオロ-4-(トリフルオロメチル)フェニル)カルバムイミドイル)ピロリジン-1-カルボキシイミドアミド;
N-(N-(3-フルオロ-4-(トリフルオロメチル)フェニル)カルバムイミドイル)ピペリジン-1-カルボキシイミドアミド;
N-(N-(4-フルオロ-3-(トリフルオロメトキシ)フェニル)カルバムイミドイル)ピペリジン-1-カルボキシイミドアミド;
N-(N-(4-クロロ-3-(トリフルオロメトキシ)フェニル)カルバムイミドイル)ピペリジン-1-カルボキシイミドアミド;
N-(N-(3-フルオロ-4-(トリフルオロメトキシ)フェニル)カルバムイミドイル)アゼチジン-1-カルボキシイミドアミド;
N-(N-(3-フルオロ-4-(トリフルオロメトキシ)フェニル)カルバムイミドイル)ピロリジン-1-カルボキシイミドアミド;
N-(N-(3-フルオロ-4-(トリフルオロメトキシ)フェニル)カルバムイミドイル)ピペリジン-1-カルボキシイミドアミド;
N-(N-(3-クロロ-4-(トリフルオロメトキシ)フェニル)カルバムイミドイル)アゼチジン-1-カルボキシイミドアミド;
N-(N-(3-クロロ-4-(トリフルオロメトキシ)フェニル)カルバムイミドイル)ピロリジン-1-カルボキシイミドアミド;
N-(N-(3-クロロ-4-(トリフルオロメトキシ)フェニル)カルバムイミドイル)ピペリジン-1-カルボキシイミドアミド;
N-(N-(3,4-ジフルオロフェニル)カルバムイミドイル)ピペリジン-1-カルボキシイミドアミド;
N-(N-(3,5-ジフルオロフェニル)カルバムイミドイル)ピペリジン-1-カルボキシイミドアミド;
N-(N-(3,5-ジクロロフェニル)カルバムイミドイル)ピペリジン-1-カルボキシイミドアミド;
N-(N-(3,4-ジクロロフェニル)カルバムイミドイル)ピロリジン-1-カルボキシイミドアミド;
N-(N-(3,4-ジクロロフェニル)カルバムイミドイル)ピペリジン-1-カルボキシイミドアミド;
N-(N-(3-クロロ-5-(トリフルオロメトキシ)フェニル)カルバムイミドイル)ピペリジン-1-カルボキシイミドアミド;
N-(N-(3-ブロモ-5-(トリフルオロメトキシ)フェニル)カルバムイミドイル)ピロリジン-1-カルボキシイミドアミド;
N-(N-(3-ブロモ-5-(トリフルオロメトキシ)フェニル)カルバムイミドイル)ピペリジン-1-カルボキシイミドアミド;又は
N-(N-(3,4,5-トリフルオロフェニル)カルバムイミドイル)ピペリジン-1-カルボキシイミドアミドでも良い。化学式1の化合物はN-(N-(4-(トリフルオロメチル)フェニル)カルバムイミドイル)ピロリジン-1-カルボキシイミドアミド又はN-(N-(4-(トリフルオロメトキシ)フェニル)カルバムイミドイル)ピロリジン-1-カルボキシイミドアミドであるのが好ましい。
nは1〜3の整数であり;
各R3はそれぞれ独立にヒドロキシ,C1-6アルキル,C1-6アルコキシ,C1-6アルキルチオ,アミノ,アセトアミド,アルキルスルホンアミド,テトラゾリル,スルホン酸及びスルファモイルからなる群から選ばれたものであり、C1-6アルキル又はC1-6アルコキシはそれぞれ独立にハロゲン又はヒドロキシから選ばれた少なくとも1つの置換基で置換されており、アミノは非置換であるかC1-6アルキルに置換されているか;又は
(2)R1及びR2はともに窒素に結合して、アゼチジニル又はアゼパニルを形成し;
nは0〜3の整数であり;
R3が複数ある場合、各R3はそれぞれ独立に水素,ハロゲン,C1-6アルキル及びC1-6アルコキシからなる群から選ばれたものであり、C1-6アルキル又はC1-6アルコキシはそれぞれ独立に非置換であるか、ハロゲン又はヒドロキシから選ばれた少なくとも1つの置換基で置換されている。
図2は、本発明の化学式1の化合物のSnail発現抑制効果を示す免疫プロット法の結果を示す。
ピペリジン(92.8 ml,0.940 mol)をブタノール(300 ml)に溶解することにより調製した溶液に濃塩酸(81.7 ml,0.940 mol)を添加し、0°Cで30分撹拌した。得られた混合溶液にナトリウムジシアンアミド(92.0 g,1.03 mol)を添加し、得られた反応混合物を24時間還流撹拌した。反応終了を確認した後、反応混合物を濾過して生成された塩化ナトリウムを除去し、濾過液を減圧濃縮した。蒸留水(100 ml)を濃縮物に添加し、室温で1時間撹拌した。生成された固体を濾過し、濾過物を蒸留水(2×20 ml)で洗浄した。濾過物を減圧乾燥し、白色固体の目的化合物(93.3 g,65%)を得た。
1H NMR (600 MHz,DMSO-d6) δ 7.01(br,s,2H),3.39(m,4H),1.54(m,2H),1.42(m,4H);LC-MS m/z 153.2 [M+1]+;mp 163-165°C
1H NMR (600 MHz,DMSO-d6) δ 6.92(br,s,2H),3.91(t,J =7.8 Hz,4H),2.16(tt,J =7.8,7.8 Hz,2H);LC-MS m/z 125.2[M+1]+;mp 188-189°C
1H NMR (600 MHz,DMSO-d6) δ 6.88(br,s,2H),3.24(m,4H),1.80(m,4H);LC-MS m/z 139.2[M+1]+;mp 232-235°C
1H NMR (600 MHz,DMSO-d6) δ 6.88(br,s,2H),3.38(m,4H),1.59(m,4H),1.45(m,4H);LC-MS m/z 167.2[M+1]+;mp 168-170°C
1H NMR (600 MHz,DMSO-d6) δ 7.12(br,s,2H),3.51(m,4H),3.35(m,4H);LC-MS m/z 155.1[M+1]+;mp 171-173°C
1H NMR (600 MHz,DMSO-d6) δ 7.12(br,s,2H),3.39(t,J =4.8 Hz,4H),2.24(t,J =4.8 Hz,4H),2.15(s,3H);LC-MS m/z 168.2[M+1]+;mp 192-194°C
1H NMR (600 MHz,DMSO-d6) δ 9.88(br,s,1H),7.76(br,s,1H),7.72(s,1H),7.30(ddd,J =7.8,1.2,0.6 Hz,1H),7.24(dd,J =7.8,7.8 Hz,1H),7.19(dd,J =7.8,0.6 Hz,1H),6.93(br,s,2H),3.45(m,4H),1.58(m,2H),1.55(m,4H);LC-MS m/z 324.1[M+1]+;mp 263-264°C
Amberlyst(R) A26(OH)イオン交換樹脂(30g)をメタノール(20 ml)に溶解することにより得られた溶液を室温10分撹拌し、イオン交換樹脂をカラム(直径:3cm,高さ:80 cm)に充填した。その後、メタノール(200 ml)をカラムに通した。実施例26で調製した塩酸塩(2.82 g,7.67 mmol)をメタノール(3 ml)に溶解することにより得られた溶液をカラムに充填し、メタノール(200 ml)をカラムに通した。採取した溶液を減圧濃縮し、白色固体を得た。その後、エチル酢酸塩(100 ml)を白色固体に添加し、10分撹拌した。得られた混合物を濾過した後、濾過液を減圧濃縮し、N1-ピロリジン-N5-(4-トリフルオロメチル)フェニルビグアニドの遊離塩基を白色固体(2.37 g,93%)として得た。遊離塩基はさらに精製することなく次の段階で用いた。
1H NMR (600 MHz,CD 3 OD) δ 7.61(d,J =9.0 Hz,2H),7.57(d,J =9.0 Hz,2H),3.51(t,J =6.0 Hz,2H),3.43(t,J =6.0 Hz,2H),2.07(m,2H),1.94(m,2H),1.90(s,3H);LC-MS m/z 300.2[M+1]+;mp 202-204°C
1) 1mlの蒸留水を室温で5mgの塩を含む容器に添加する。
2) 得られた混合物を10分撹拌した後、室温で1時間静置する。
3) 未溶解の残留塩を回収し、秤量する。
4) 回収した塩と溶解した塩の量比を算出する。
5) 塩の量を増やしながら(例えば10,15,20,25及び30 mg)、段階1)〜4)を繰り返し行う。
以下の実験例に記載の方法により、本発明の実施例に記載の方法により合成した化合物をAMPK活性化及び癌細胞増殖の抑制効果で評価した
人間の乳癌細胞に由来したMCF7細胞(韓国細胞株バンクから市販されている)を使用し、ビグアニド誘導体のAMPK活性化効果をAMPKα免疫測定キット(Invitrogen,カタログNo. KHO0651)を用いて確認した。
*:参考例
人間の大腸癌に由来したHCT116細胞(韓国細胞株バンクから市販されている)を使用し、3-(4,5-ジメチルチアゾル-2-イル)-2,5-ジフェニルテトラゾリウムブロミド(MTT)試剤を用いて細胞増殖が50%に抑制される濃度値(細胞増殖抑制濃度,GIC50)を測定し、ビグアニド誘導体の癌細胞増殖の抑制効果を確認した。
*:参考例
癌幹細胞は、幹細胞が特質上先天的に備える自己再生又は分化能力を有する癌細胞である。ここで、癌幹細胞は従来の抗癌療法に対する耐性及び予後不良を示す。そのためビグアニド誘導体は、癌幹細胞、特に乳癌幹細胞(マンモスフィア)の生成及び増殖を抑制することにより、癌再発を抑制する効果を有する。従って、乳癌幹細胞(マンモスフィア)の生成を抑制するビグアニド誘導体の効果をマンモスフィアを形成する人間の乳癌に由来したMCF7細胞株で測定した。実験方法を以下に簡単に記載する。
種々のサイトカイン及び増殖因子によりEMTを起こした細胞は運動能を有し、新しい組織に腫瘍を形成するために距離を移動することができる。そのため、EMTを妨げるためにEMTに関連する転写因子の発現を調節することにより、癌の転移細胞を抑制することができる。これらの事実に基づいて、人間の乳癌に由来したMCF7細胞株内のEMTを含む転写因子であるSnailの発現を抑制するビグアニド誘導体の活性を測定した。実験方法を以下に簡単に示す。
Claims (13)
- 化学式1の化合物又はその薬学的に許容される塩。
nは1〜3の整数であり;
各R3はそれぞれ独立にヒドロキシ,C1-6アルキル,C1-6アルコキシ,C1-6アルキルチオ,アミノ,アセトアミド,アルキルスルホンアミド,テトラゾリル,スルホン酸及びスルファモイルからなる群から選ばれたものであり、C1-6アルキル又はC1-6アルコキシはそれぞれ独立にハロゲン又はヒドロキシから選ばれた少なくとも1つの置換基で置換されており、アミノは非置換であるかC1-6アルキルに置換されているか;又は
(2)R1及びR2はともに窒素に結合して、アゼチジニル又はアゼパニルを形成し;
nは0〜3の整数であり;
R3が複数ある場合、各R3はそれぞれ独立に水素,ハロゲン,C1-6アルキル及びC1-6アルコキシからなる群から選ばれたものであり、C1-6アルキル又はC1-6アルコキシはそれぞれ独立に非置換であるか、少なくともハロゲン又はヒドロキシから選ばれた少なくとも1つの置換基で置換されている。] - R1及びR2はともに窒素に結合してピロリジニル又はピペリジニルを形成し;
nは1又は2であり;
各R3はそれぞれ独立にハロアルキル及びハロアルコキシからなる群から選ばれたものであることを特徴とする請求項1に記載の化学式1の化合物又はその薬学的に許容される塩。 - 化学式1の化合物又はその薬学的に許容される塩であって、
N-(N-(3-ブロモフェニル)カルバムイミドイル)ピペリジン-1-カルボキシイミドアミド;
N-(N-m-トリルカルバムイミドイル)ピペリジン-1-カルボキシイミドアミド;
N-(N-(3-エチルフェニル)カルバムイミドイル)ピペリジン-1-カルボキシイミドアミド;
N-(N-(3-ヒドロキシフェニル)カルバムイミドイル)ピペリジン-1-カルボキシイミドアミド;
N-(N-(3-(ヒドロキシメチル)フェニル)カルバムイミドイル)ピペリジン-1-カルボキシイミドアミド;
N-(N-(3-フルオロフェニル)カルバムイミドイル)ピペリジン-1-カルボキシイミドアミド;
N-(N-(3-クロロフェニル)カルバムイミドイル)ピロリジン-1-カルボキシイミドアミド;
N-(N-(3-クロロフェニル)カルバムイミドイル)ピペリジン-1-カルボキシイミドアミド;
N-(N-(3-クロロフェニル)カルバムイミドイル)アゼパン-1-カルボキシイミドアミド;
N-(N-(3-(トリフルオロメチル)フェニル)カルバムイミドイル)ピロリジン-1-カルボキシイミドアミド;
N-(N-(3-(トリフルオロメチル)フェニル)カルバムイミドイル)ピペリジン-1-カルボキシイミドアミド;
N-(N-(4-(トリフルオロメチル)フェニル)カルバムイミドイル)アゼチジン-1-カルボキシイミドアミド;
N-(N-(4-(トリフルオロメチル)フェニル)カルバムイミドイル)ピペリジン-1-カルボキシイミドアミド;
N-(N-(3-(トリフルオロメトキシ)フェニル)カルバムイミドイル)ピロリジン-1-カルボキシイミドアミド;
N-(N-(3-(トリフルオロメトキシ)フェニル)カルバムイミドイル)ピペリジン-1-カルボキシイミドアミド;
N-(N-(3-(ジフルオロメトキシ)フェニル)カルバムイミドイル)ピペリジン-1-カルボキシイミドアミド;
N-(N-(4-(トリフルオロメトキシ)フェニル)カルバムイミドイル)アゼチジン-1-カルボキシイミドアミド;
N-(N-(4-(トリフルオロメトキシ)フェニル)カルバムイミドイル)ピペリジン-1-カルボキシイミドアミド;
4-メチル-N-(N-(4-(トリフルオロメトキシ)フェニル)カルバムイミドイル)ピペラジン-1-カルボキシイミドアミド;
N-(N-(3-アミノフェニル)カルバムイミドイル)ピペリジン-1-カルボキシイミドアミド;
N-(N-(4-(ジメチルアミノ)フェニル)カルバムイミドイル)ピペリジン-1-カルボキシイミドアミド;
N-(4-(3-(イミノ(ピペリジン-1-イル)メチル)グアニジノ)フェニル)アセトアミド;
N-(3-(3-(イミノ(ピペリジン-1-イル)メチル)グアニジノ)フェニル)アセトアミド;
N-(N-(4-(1H-テトラゾール-5-イル)フェニル)カルバムイミドイル)ピペリジン-1-カルボキシイミドアミド;
N-(N-(3-(メチルサルフォンアミド)フェニル)カルバムイミドイル)ピペリジン-1-カルボキシイミドアミド;
4-(3-(イミノ(ピペリジン-1-イル)メチル)グアニジノ)ベンゼンスルホン酸;
N-(N-(4-(メチルチオ)フェニル)カルバムイミドイル)ピペリジン-1-カルボキシイミドアミド;
N-(N-(4-スルファモイルフェニル)カルバムイミドイル)ピペリジン-1-カルボキシイミドアミド;
N-(N-(4-フルオロ-3-(トリフルオロメチル)フェニル)カルバムイミドイル)ピペリジン-1-カルボキシイミドアミド;
N-(N-(4-クロロ-3-(トリフルオロメチル)フェニル)カルバムイミドイル)ピペリジン-1-カルボキシイミドアミド;
N-(N-(3-フルオロ-4-(トリフルオロメチル)フェニル)カルバムイミドイル)ピロリジン-1-カルボキシイミドアミド;
N-(N-(3-フルオロ-4-(トリフルオロメチル)フェニル)カルバムイミドイル)ピペリジン-1-カルボキシイミドアミド;
N-(N-(4-フルオロ-3-(トリフルオロメトキシ)フェニル)カルバムイミドイル)ピペリジン-1-カルボキシイミドアミド;
N-(N-(4-クロロ-3-(トリフルオロメトキシ)フェニル)カルバムイミドイル)ピペリジン-1-カルボキシイミドアミド;
N-(N-(3-フルオロ-4-(トリフルオロメトキシ)フェニル)カルバムイミドイル)アゼチジン-1-カルボキシイミドアミド;
N-(N-(3-フルオロ-4-(トリフルオロメトキシ)フェニル)カルバムイミドイル)ピロリジン-1-カルボキシイミドアミド;
N-(N-(3-フルオロ-4-(トリフルオロメトキシ)フェニル)カルバムイミドイル)ピペリジン-1-カルボキシイミドアミド;
N-(N-(3-クロロ-4-(トリフルオロメトキシ)フェニル)カルバムイミドイル)アゼチジン-1-カルボキシイミドアミド;
N-(N-(3-クロロ-4-(トリフルオロメトキシ)フェニル)カルバムイミドイル)ピロリジン-1-カルボキシイミドアミド;
N-(N-(3-クロロ-4-(トリフルオロメトキシ)フェニル)カルバムイミドイル)ピペリジン-1-カルボキシイミドアミド;
N-(N-(3,4-ジフルオロフェニル)カルバムイミドイル)ピペリジン-1-カルボキシイミドアミド;
N-(N-(3,5-ジフルオロフェニル)カルバムイミドイル)ピペリジン-1-カルボキシイミドアミド;
N-(N-(3,5-ジクロロフェニル)カルバムイミドイル)ピペリジン-1-カルボキシイミドアミド;
N-(N-(3,4-ジクロロフェニル)カルバムイミドイル)ピロリジン-1-カルボキシイミドアミド;
N-(N-(3,4-ジクロロフェニル)カルバムイミドイル)ピペリジン-1-カルボキシイミドアミド;
N-(N-(3-クロロ-5-(トリフルオロメトキシ)フェニル)カルバムイミドイル)ピペリジン-1-カルボキシイミドアミド;
N-(N-(3-ブロモ-5-(トリフルオロメトキシ)フェニル)カルバムイミドイル)ピロリジン-1-カルボキシイミドアミド;
N-(N-(3-ブロモ-5-(トリフルオロメトキシ)フェニル)カルバムイミドイル)ピペリジン-1-カルボキシイミドアミド;又は
N-(N-(3,4,5-トリフルオロフェニル)カルバムイミドイル)ピペリジン-1-カルボキシイミドアミドであることを特徴とする化学式1の化合物又はその薬学的に許容される塩。 - 化学式1の化合物がN-(N-(4-(トリフルオロメチル)フェニル)カルバムイミドイル)ピロリジン-1-カルボキシイミドアミドであることを特徴とする請求項1に記載の化学式1の化合物又はその薬学的に許容される塩。
- 化学式1の化合物がN-(N-(4-(トリフルオロメトキシ)フェニル)カルバムイミドイル)ピロリジン-1-カルボキシイミドアミドであることを特徴とする請求項1に記載の化学式1の化合物又はその薬学的に許容される塩。
- 前記薬学的に許容される塩はギ酸,酢酸,プロピオン酸,乳酸,酪酸,イソ酪酸,トリフルオロ酢酸,リンゴ酸,マイレン酸,マロン酸,フマル酸,コハク酸,コハク酸モノアミド,グルタミン酸,酒石酸,シュウ酸,クエン酸,グリコール酸,グルクロン酸,アスコルビン酸,安息香酸,フタル酸,サルチル酸,アントラニル酸,ベンゼンスルホン酸,p-トルエンスルホン酸,メタンスルホン酸,ジクロロ酢酸,アミノオキシ酢酸,塩酸,臭化水素酸,硫酸,リン酸,硝酸,炭酸及びホウ酸からなる群から選ばれた酸の塩であることを特徴とする請求項1に記載の化学式1の化合物又はその薬学的に許容される塩。
- 化学式2の化合物とジシアノアミドを有機溶媒中で反応させて化学式3の化合物を生成し、化学式3の化合物と化学式4の化合物を水,有機溶媒又はその混合物中で反応させて化学式1の化合物を得ることを特徴とする化学式1の化合物の調製方法。
nは1〜3の整数であり;
各R3はそれぞれ独立にヒドロキシ,C1-6アルキル,C1-6アルコキシ,C1-6アルキルチオ,アミノ,アセトアミド,アルキルスルホンアミド,テトラゾリル,スルホン酸及びスルファモイルからなる群から選ばれたものであり、C1-6アルキル又はC1-6アルコキシはそれぞれ独立にハロゲン又はヒドロキシから選ばれた少なくとも1つの置換基で置換されており、アミノは非置換であるかC1-6アルキルに置換されているか;又は
(2)R1及びR2はともに窒素に結合して、アゼチジニル又はアゼパニルを形成し;
nは0〜3の整数であり;
R3が複数ある場合、各R3はそれぞれ独立に水素,ハロゲン,C1-6アルキル及びC1-6アルコキシからなる群から選ばれたものであり、C1-6アルキル又はC1-6アルコキシはそれぞれ独立に非置換であるか、ハロゲン又はヒドロキシから選ばれた少なくとも1つの置換基で置換されている。] - 請求項1〜6のいずれかに記載の化合物又はその薬学的に許容される塩を有効成分として含む薬。
- 糖尿病,肥満,高脂血症,高コレステロール血症,脂肪肝,冠動脈疾患,骨粗鬆症,多嚢胞性卵巣症候群,メタボリック症候群,癌,筋肉痛,筋細胞損傷及び横紋筋融解症からなる群から選ばれた疾患を予防又は治療するための化学式1の化合物又はその薬学的に許容される塩を有効成分として含む医薬組成物であって、
nは1〜3の整数であり;
各R3はそれぞれ独立にヒドロキシ,C1-6アルキル,C1-6アルコキシ,C1-6アルキルチオ,アミノ,アセトアミド,アルキルスルホンアミド,テトラゾリル,スルホン酸及びスルファモイルからなる群から選ばれたものであり、C1-6アルキル及びC1-6アルコキシはそれぞれ独立にハロゲン又はヒドロキシから選ばれた少なくとも1つの置換基で置換されており、アミノは非置換であるかC1-6アルキルに置換されているか、;又は
(2)R 1 及びR 2 はともに窒素に結合して、アゼチジニル又はアゼパニルを形成し;
nは0〜3の整数であり;
R 3 が複数ある場合、各R 3 はそれぞれ独立に水素,ハロゲン,C 1-6 アルキル及びC 1-6 アルコキシからなる群から選ばれたものであり、C 1-6 アルキル又はC 1-6 アルコキシはそれぞれ独立に非置換であるか、少なくともハロゲン又はヒドロキシから選ばれた少なくとも1つの置換基で置換されていることを特徴とする医薬組成物。 - 前記糖尿病はインスリン依存型糖尿病であることを特徴とする請求項9に記載の医薬組成物。
- 前記癌の治療は癌の再発又は転移の抑制を含むことを特徴とする請求項9に記載の医薬組成物。
- 前記癌は子宮癌,乳癌,胃癌,脳癌,大腸癌,肺癌,皮膚癌,血液癌及び肝臓癌からなる群から選ばれた疾患であることを特徴とする請求項9に記載の医薬組成物。
- 前記医薬組成物は錠剤,カプセル剤,丸剤,粒剤,顆粒剤,注射剤又は液剤として製剤化されることを特徴とする請求項9に記載の医薬組成物。
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR20110078764 | 2011-08-08 | ||
KR10-2011-0078764 | 2011-08-08 | ||
KR10-2011-0089272 | 2011-09-02 | ||
KR20110089272 | 2011-09-02 | ||
PCT/KR2012/006326 WO2013022278A2 (en) | 2011-08-08 | 2012-08-08 | N1-cyclic amine-n5-substituted phenyl biguanide derivatives, methods of preparing the same and pharmaceutical composition comprising the same |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2014524424A JP2014524424A (ja) | 2014-09-22 |
JP5927518B2 true JP5927518B2 (ja) | 2016-06-01 |
Family
ID=47669085
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2014524932A Active JP5927518B2 (ja) | 2011-08-08 | 2012-08-08 | N1−環状アミン−n5−置換フェニルビグアニド誘導体、それの調製方法及びそれを含む医薬組成物 |
Country Status (8)
Country | Link |
---|---|
US (1) | US9540325B2 (ja) |
EP (1) | EP2742019B1 (ja) |
JP (1) | JP5927518B2 (ja) |
KR (1) | KR101425061B1 (ja) |
CN (1) | CN103827083B (ja) |
DK (1) | DK2742019T3 (ja) |
ES (1) | ES2869423T3 (ja) |
WO (1) | WO2013022278A2 (ja) |
Families Citing this family (22)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR102034899B1 (ko) * | 2013-02-07 | 2019-10-22 | 이뮤노메트테라퓨틱스 인코포레이티드 | Ν1-고리아민-ν5-치환된 바이구아나이드 유도체, 이의 제조방법 및 이를 유효성분으로 함유하는 약학 조성물 |
WO2014123364A1 (en) | 2013-02-07 | 2014-08-14 | Hanall Biopharma Co., Ltd. | N1-cyclic amine-n5-substituted biguanide derivatives, methods of preparing the same and pharmaceutical composition comprising the same |
KR102088001B1 (ko) * | 2013-05-23 | 2020-03-12 | 이뮤노메트테라퓨틱스 인코포레이티드 | N1-고리아민-n5-치환된 바이구아나이드 유도체를 유효성분으로 함유하는 섬유화 예방 또는 치료용 약학 조성물 |
KR102192726B1 (ko) * | 2013-11-04 | 2020-12-18 | 이뮤노메트테라퓨틱스 인코포레이티드 | 바이구아나이드 화합물 및 이의 용도 |
KR102310185B1 (ko) * | 2013-11-04 | 2021-10-12 | 이뮤노메트테라퓨틱스 인코포레이티드 | 바이구아나이드 화합물 및 이의 용도 |
CN104230760B (zh) * | 2014-09-02 | 2016-07-06 | 浙江工业大学 | N-芳基取代的双胍氢溴酸盐类化合物及制备方法和应用 |
CN104262205B (zh) * | 2014-09-02 | 2017-04-12 | 浙江工业大学 | N‑芳基双胍氢碘酸盐类化合物及其制备方法和应用 |
CA2984119C (en) * | 2015-04-30 | 2022-04-26 | Immunomet Therapeutics Inc. | Guanidine compounds and use thereof |
KR102253478B1 (ko) * | 2015-05-13 | 2021-05-20 | 이뮤노메트테라퓨틱스 인코포레이티드 | 바이구아나이드 유도체를 유효성분으로 포함하는 교모세포종 예방 또는 치료용 의약 조성물 |
WO2017093912A1 (en) * | 2015-11-30 | 2017-06-08 | Glaxosmithkline Intellectual Property (No.2) Limited | Formulations for intravenous injection of danirixin |
TWI680122B (zh) * | 2016-09-07 | 2019-12-21 | 國立陽明大學 | 活化腺苷單磷酸活化蛋白激酶之化合物 |
US10344002B2 (en) | 2016-09-26 | 2019-07-09 | Nusirt Sciences, Inc. | Compositions and methods for treating metabolic disorders |
US20200038347A1 (en) * | 2017-01-24 | 2020-02-06 | Industry-Academic Cooperation Foundation, Yonsei University | Pharmaceutical compositions for preventing or treating inflammatory disease, autoimmune disease, or combination thereof, and method for using same |
US20190046478A1 (en) * | 2017-08-10 | 2019-02-14 | The Royal Institution For The Advancement Of Learning/Mcgill University | Biological marker for identifying cancer patients for treatment with a biguanide |
CA3079952A1 (en) * | 2017-10-24 | 2019-05-02 | Lunella Biotech, Inc. | Mitoflavoscins: targeting flavin-containing enzymes eliminates cancer stem cells (cscs) by inhibiting mitochondrial respiration |
WO2020232056A1 (en) * | 2019-05-13 | 2020-11-19 | The Regents Of The University Of California | Compositions and methods for the treatment of neurological diseases and disorders |
CN110357795B (zh) * | 2019-07-26 | 2021-10-29 | 湖南师范大学 | 一种双胍衍生物、药物组合物、制备方法和其在制备抗肿瘤药物中的应用 |
CN110615886A (zh) * | 2019-09-05 | 2019-12-27 | 哈尔滨工程大学 | 一种双胍衍生物抗菌型环氧树脂固化剂及其制备方法 |
KR102552913B1 (ko) * | 2019-12-02 | 2023-07-07 | 주식회사 하임바이오 | 알데히드 억제제 및 비구아나이드 계열 화합물을 포함하는 속발성 암의 예방 및 치료용 약학조성물 |
WO2023278300A1 (en) * | 2021-06-28 | 2023-01-05 | ImmunoMet Therapeutics, Inc. | Solid dosage form of n-1-pyrrolidine-n-5-(3-trifluoromethoxy)phenyl biguanide and uses thereof |
CN114671830A (zh) * | 2022-04-24 | 2022-06-28 | 西安石油大学 | 一种双胍衍生物盐酸盐的制备方法 |
CN115261355B (zh) * | 2022-09-14 | 2023-07-28 | 广东医科大学 | AMPKα1琥珀酰化修饰及应用 |
Family Cites Families (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2467371A (en) * | 1944-05-10 | 1949-04-19 | Ici Ltd | Biguanide derivatives |
GB599714A (en) | 1945-10-08 | 1948-03-18 | Robert De Brath Ashworth | Manufacture of biguanide derivatives |
FR6786M (ja) | 1967-08-10 | 1969-03-17 | ||
US3960949A (en) * | 1971-04-02 | 1976-06-01 | Schering Aktiengesellschaft | 1,2-Biguanides |
FR2809310B1 (fr) * | 2000-05-26 | 2004-02-13 | Centre Nat Rech Scient | Utilisation de derives de biguanide pour fabriquer un medicament ayant un effet cicatrisant |
KR100772531B1 (ko) | 2001-06-30 | 2007-11-01 | 주식회사 하이닉스반도체 | 캐패시터의 제조 방법 |
HUP0300990A2 (hu) | 2003-04-15 | 2005-05-30 | SynoSens Kutató és Fejlesztő Kft. | Szinergista gyógyszer-kombináció a diabetesz megelőzésére vagy kezelésére |
CN1846694B (zh) | 2005-04-12 | 2012-02-01 | 中国医学科学院血液学研究所 | 取代芳香基双胍类化合物及含它们的药物组合物在制备抗恶性肿瘤药物方面的应用 |
US20110263901A1 (en) * | 2008-01-23 | 2011-10-27 | Dhananjay Govind Sathe | Process of Preparation of Proguanil |
KR101136045B1 (ko) * | 2009-11-16 | 2012-04-18 | 한국화학연구원 | N1-(펜에틸)-n2-치환된 바이구아나이드 유도체, 이의 제조방법 및 이를 유효성분으로 함유하는 약학 조성물 |
JP2013516461A (ja) | 2010-01-06 | 2013-05-13 | ハナル バイオファーマ カンパニー リミテッド | ビグアニド誘導体、その製造方法及びこれを有効成分として含有する薬学組成物 |
-
2012
- 2012-08-08 WO PCT/KR2012/006326 patent/WO2013022278A2/en active Application Filing
- 2012-08-08 EP EP12821403.8A patent/EP2742019B1/en active Active
- 2012-08-08 JP JP2014524932A patent/JP5927518B2/ja active Active
- 2012-08-08 ES ES12821403T patent/ES2869423T3/es active Active
- 2012-08-08 KR KR1020120086999A patent/KR101425061B1/ko active IP Right Grant
- 2012-08-08 US US14/237,514 patent/US9540325B2/en active Active
- 2012-08-08 CN CN201280038931.XA patent/CN103827083B/zh active Active
- 2012-08-08 DK DK12821403.8T patent/DK2742019T3/da active
Also Published As
Publication number | Publication date |
---|---|
EP2742019A4 (en) | 2015-01-07 |
EP2742019A2 (en) | 2014-06-18 |
US9540325B2 (en) | 2017-01-10 |
DK2742019T3 (da) | 2021-05-25 |
JP2014524424A (ja) | 2014-09-22 |
ES2869423T3 (es) | 2021-10-25 |
KR101425061B1 (ko) | 2014-08-06 |
CN103827083A (zh) | 2014-05-28 |
CN103827083B (zh) | 2016-03-09 |
WO2013022278A3 (en) | 2013-04-25 |
US20140179660A1 (en) | 2014-06-26 |
KR20130019351A (ko) | 2013-02-26 |
EP2742019B1 (en) | 2021-03-03 |
WO2013022278A2 (en) | 2013-02-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP5927518B2 (ja) | N1−環状アミン−n5−置換フェニルビグアニド誘導体、それの調製方法及びそれを含む医薬組成物 | |
US9321742B2 (en) | N1-cyclic amine-N5-substituted biguanide derivatives, methods of preparing the same and pharmaceutical composition comprising the same | |
JP6677739B2 (ja) | ビグアニド化合物及びその使用 | |
US10252996B2 (en) | N1-cyclic amine-N5-substituted biguanide derivatives, methods of preparing the same and pharmaceutical composition comprising the same | |
TW200808807A (en) | Modulators of 11-β hydroxyl steroid dehydrogenase type 1, pharmaceutical compositions thereof, and methods of using the same | |
JP5897566B2 (ja) | 環式n,n’−ジアリールチオ尿素及びn,n’−ジアリール尿素−アンドロゲン受容体アンタゴニスト、抗癌剤、その調製のための方法及び使用 | |
JPH06502183A (ja) | 新規な4−アリールピペラジン類および4−アリールピペリジン類 | |
BRPI0712631A2 (pt) | "compostos, processo para a preparação de um composto, composição farmacêutica, uso de um composto e combinações" | |
ES2249722T3 (es) | Antagonistas de receptor de opioides. | |
ES2390459T3 (es) | Antagonistas de receptores de opioides | |
CN108368046A (zh) | 哌啶酮甲酰肽2受体和甲酰肽1受体激动剂 | |
BR112020005064A2 (pt) | aminas beta-hidróxi heterocíclicas e seu uso no tratamento de hiperglicemia | |
AU2012335980A1 (en) | Modulators of opioid receptors and methods of use thereof | |
TW201920135A (zh) | 吡唑衍生化合物及其用途 | |
KR20130018623A (ko) | N1-고리아민-n2-치환된 바이구아나이드 유도체, 이의 제조방법 및 이를 유효성분으로 함유하는 약학 조성물 | |
TW200843748A (en) | New combination 629 | |
KR101994145B1 (ko) | Ν1-고리아민-ν5-치환된 바이구아나이드 유도체를 유효성분으로 함유하는 시차증후군의 예방 또는 치료용 약학 조성물 | |
KR102034899B1 (ko) | Ν1-고리아민-ν5-치환된 바이구아나이드 유도체, 이의 제조방법 및 이를 유효성분으로 함유하는 약학 조성물 | |
RU2776842C2 (ru) | Применение агониста kor в комбинации с агонистом mor для получения лекарственного средства для лечения боли | |
US6303608B1 (en) | 2-{4-[4-(4,5-dichloro-2-methylimidazol-1-yl)butyl]-1-piperazinyl}-5-fluoropyrimidine, its preparation and its therapeutic use | |
KR102072245B1 (ko) | Ν1-고리아민-ν5-치환된 바이구아나이드 유도체, 이의 제조방법 및 이를 유효성분으로 함유하는 약학 조성물 | |
WO2023166351A1 (zh) | 组胺h3受体抑制剂及其医药用途 | |
TW202210069A (zh) | 聯芳磺胺類及其醫藥組合物與彼等用於治療纖維化肺疾病之用途 | |
US3981876A (en) | 1-Alkyl-4-(10[1-piperidyl]-5H-dibenzo-[a,d]cyclohepten-5-ylidene)piperidine compounds | |
KR20150051016A (ko) | 구아니딘 화합물 및 이의 용도 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20150106 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20150401 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20150507 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20150908 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20160108 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20160113 |
|
A911 | Transfer to examiner for re-examination before appeal (zenchi) |
Free format text: JAPANESE INTERMEDIATE CODE: A911 Effective date: 20160203 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20160223 |
|
A711 | Notification of change in applicant |
Free format text: JAPANESE INTERMEDIATE CODE: A711 Effective date: 20160315 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20160315 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20160315 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 5927518 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |